Cancer | Montefiore Einstein

Jeffrey E. Segall

Read more about Jeffrey E. Segall

Jeffrey E. Segall

https://assets.montefioreeinstein.org/profiles/images/Segall_Jeffrey_PhD_2x.jpg

Faculty

Expert

First Name

Jeffrey

Last Name

Segall

Faculty ID

8206

Patient Type

Adult

Department

einstein-dept-pathology

jeffrey.segall@einsteinmed.edu

Phone

718-430-2484

Titles

Type

Academic

Department

Department of Pathology

Department Link

Rank

Professor Emeritus

Tags

me-patientcare-cancer-research-cdtmi

me-patientcare-cancer-research-cdtmi-members

Type

Administrative

Title

Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Golding Building

Room

603

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

As of July 1, 2023 I have shifted to emeritus status.  My deepest thanks and gratitude for the many students and colleagues with whom I have collaborated over the past forty years.  I have closed my lab and am no longer taking on new staff.  However, I am happy to collaborate and discuss research by zoom or in person.
My scientific interests remain focused on the mechanisms by which tumor cells invade and metastasize. Tumor cell motility and the orientation of tumor cells by chemotaxis make important contributions to invasion and metastasis.  My expertise is in breast cancer, head and neck cancer, and glioblastoma. Breast cancer, although the primary tumor can be fully removed, metastasizes to distant sites, and the resulting metastases can lead to poor prognosis.  Glioblastoma and head and neck cancer invade locally into critical areas and the primary tumors are not fully removable by surgery.  I have familiarity with tissue culture studies of invasion and signaling of these cancers and in vivo analysis in mice. 
In addition, due to my long time association with the Einstein Senate, I am working on bringing all the minutes of the Senate along with brief summaries onto the Einstein website.  Einstein is a remarkable medical school with accomplishments that we are all proud of.  The minutes provide an interesting perspective on the trials and triumphs of this amazing place.

Research Areas

mechanisms of tumor cell invasion, intravasation and metastasis; mechanical effects of the tumor microenvironment; macrophage tumor cell interactions; breast cancer; head and neck cancer; glioblastoma; intravital imaging

Specialties

Cancer

Expert Tags

Cancer Biology

Imaging

Areas of Expertise

Brain cancer

Breast cancer

Glioblastoma

Head and neck cancer

Expert Summary

Dr. Segall studies how tumor cells invade tissues and spread through the body. He has developed sophisticated imaging methods for following individual tumor cells moving in living animals. For example, one of his techniques involves a tiny glass window implanted in the skin of a mouse that allows scientists to track individual cancer cells as they spread a tumor site and attack other parts of the body. This technique could one day be used for assessing the effectiveness of specific drugs in preventing cancer from metastasizing.
Dr. Segall studies breast cancer, head and neck cancer and glioblastoma (an aggressive form of brain cancer). He investigates how protein receptors on the surfaces of tumor cells guide the tumor cells in response to signals sent out by the local tumor microenvironment. Dr. Segall has served on study sections for the U.S. Department of Defense Breast Cancer Research Program, the American Cancer Society and the National Institutes of Health. He currently serves on the NIH’s Tumor Microenvironment study section.

Research Profile

https://einsteinmed.edu/faculty/8206/Jeffrey-Segall

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/928a83b3-17e3-4dbd-84fd-dadd257df…

Selected Publications

A.        Original Communications in Reviewed Journals
1.      Chiang, P.K., Guranowski, A. and J.E. Segall (1981) Irreversible Inhibition of S-Adenosylhomocysteine Hydrolase by Nucleoside Analogs. Arch. Bioc. Bioph. 207:175:184.
2.      Segall, J.E., Manson, M.D. and H.C. Berg. (1982) Signal Processing Times in Bacterial Chemotaxis.  Nature 296:855-857. PubMed PMID: 7040985.
3.      Block, S.M., Segall, J.E. and H.C. Berg. (1982) Impulse Responses in Bacterial Chemotaxis.  Cell 31:215-226. PubMed PMID: 6760985
4.      Block SM, Segall JE, Berg HC. Adaptation kinetics in bacterial chemotaxis. J Bacteriol. 1983 Apr;154(1):312-23. PubMed PMID: 6339475; PubMed Central PMCID: PMC217461.
5.      Ishihara A, Segall JE, Block SM, Berg HC. Coordination of flagella on filamentous cells of Escherichia coli. J Bacteriol. 1983 Jul;155(1):228-37. PubMed PMID: 6345503; PubMed Central PMCID: PMC217673.
6.      Segall, J.E., Ishihara, A. and H.C. Berg. (1985) Chemotactic Signaling in Filamentous Cells of Escherichia coli. J. Bacter. 161:51-59. PubMed PMID: 3881399; PubMed Central PMCID: PMC214834.
7.      Segall, J.E., Block, S.M, and H.C. Berg. (1986) Temporal Comparisons in Bacterial Chemotaxis.  Proc. Natl. Acad. Sci. USA 83:8987-8991. PubMed PMID: 3024160; PubMed Central PMCID: PMC387059
8.      Segall, J.E., Fisher, P.R. and G. Gerisch. (1987) Selection of Chemotaxis Mutants of Dictyostelium discoideum. J. Cell Biol. 104:151-161. PubMed PMID: 3793759; PubMed Central PMCID: PMC2117037.
9.      Segall, J.E.. (1988) Analysis of Responses of Dictyostelium discoideum Amoebae to Chemoattractant Concentration Changes. J. Muscle Res. Cell Mot. 9:481-490. PubMed PMID: 2850298.
10.   Segall, J.E.,  Bominaar, A., Wallraff, E. and R. de Wit. (1988) Analysis of a Dictyostelium Chemotaxis Mutant with Altered Chemoattractant Binding. J. Cell Sci. 91:479-489. PubMed PMID: 3255752.
11.   Andre, E., Brink, M., Gerisch, G., Isenberg, G., Noegel, A., Schleicher, M., Segall, J. E., and E. A. Wallraff. (1989)  A Dictyostelium Mutant Deficient in Severin, an F-actin Fragmenting Protein,  Shows Normal Motility and Chemotaxis. J. Cell Biol. 108:985-995. PubMed PMID: 2537840; PubMed Central PMCID: PMC2115376.
12.   Brinke, J., Gerisch, G., Isenberg, G., Noegel, A.A., Segall, J.E., Wallraff, E., and M. Schleicher. (1990) A Dictyostelium Mutant lacking an F-actin Crosslinking Protein, the 120 kD Gelation Factor.  J. Cell Biol. 111:1477-1489. PubMed PMID: 1698791; PubMed Central PMCID: PMC2116242.
13.   Barisic, K., Mollner, S., Noegel, A. A., Gerisch, G., and J. E. Segall. (1991) cDNA Sequence of Cyclophilin from Dictyostelium discoideum.  Developmental Genetics, 12:50-53. PubMed PMID: 2049879.
14.   Segall, J.E. (1992) Behavioral responses of streamer F mutants of Dictyostelium discoideum: effects of cyclic GMP on cell motility.  J. Cell Sci., 101:589-597. PubMed PMID: 1325982.
15.   Segall, J.E. (1993) Polarization of yeast cells in spatial gradients of mating factor.  Proc. Natl. Acad. Sci. 90:8332-8336. PubMed PMID: 8397402; PubMed Central PMCID: PMC47350.
16.   Segall, J.E., Kuspa, A., Shaulsky, G., Ecke, M., Maeda, M., Gaskins, C., Firtel, R.A., and W.G. Loomis. (1995) A MAP kinase necessary for receptor-mediated activation of adenylate cyclase in Dictyostelium.  J. Cell Biol. 128:405-413. PubMed PMID: 7844154; PubMed Central PMCID: PMC2120359.
17.   Segall, J.E., Tyrech, S., Boselli, L., W., Masseling, S., Chan, A., Helft, J,  Jones, J. and J. Condeelis.  (1996) EGF stimulates lamellipod extension and chemotaxis in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism.  Clin. Exp. Met. 14:61-72.
18.   Gaskins, C., Clark, A.M., Aubry, L., Segall, J.E., Firtel, R.A. (1996) The Dictyostelium MAP kinase ERK2 regulates multiple, independent developmental pathways.  Genes and Dev. 10:118-128. PubMed PMID: 8557190.
19.   Knetsch, M.L.W., Epskamp, S.J.P., Schenk, P.W., Segall, J.E., and B.E. Snaar-Jagalska. (1996) Both G-protein and ras-dependent activation of extracellular signal regulated kinase 2 is antagonized by intracellular cAMP in Dictyostelium discoideum.  EMBO J. 15:3361-3368. PubMed PMID: 8670837; PubMed Central PMCID: PMC451899.
20.   Leberer, E., Wu, C., Leeuw, T., Fourest-Lieuvin, A., Segall, J.E., and D. Y. Thomas (1996) Functional characterization of the Cdc42p binding domain of yeast Ste20p protein kinase.  EMBO J. 16:83-97. PubMed PMID: 9009270; PubMed Central PMCID: PMC1169616.
21.   Edmonds, B.T., Wyckoff, J., Yeung, Y.-G., Wang, Y., Stanley, E.R., Jones, J., Segall, J.E., and J. Condeelis (1996) Elongation factor-1alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma.  J. Cell Science 109:2705-2714.
22.   Chan, A., Raft, S., Bailly, M., Wyckoff, J., Segall, J. and Condeelis, J. (1998) EGF stimulates an increase in actin nucleation and filament number at the leading edge of the lamellipod in mammary adenocarcinoma cells.  J. Cell Sci. 111:199-211.
23.   Wang, Y., Liu, J. and J.E. Segall (1998) MAP kinase function in amoeboid chemotaxis.  J. Cell Sci. 111:373-383. PubMed PMID: 9427685.
24.   Wang, Y. and J.E. Segall (1998) The Dictyostelium MAP kinase DdERK2 functions as a cytosolic protein in complexes with its substrates in chemotactic signal transduction.  Biochem. Biophys. Res. Comm. 244:149-155. PubMed PMID: 9514860.
25.   Bailly, M., Yan, L., Whitesides, G.M., Condeelis, J.S., and J.E. Segall (1998) Regulation of protrusion shape and adhesion to the substratum during chemotactic responses of mammalian carcinoma cells.  Exp. Cell Res. 241:285-299.
26.   Farina, K., Wyckoff, J., Rivera, J., Lee, H., Segall, J., Condeelis, J. and Jones, J. (1998) Cell motility of tumor cells visualized in living intact primary tumors using green fluorescent protein.  Cancer Res. 58:2528-2532.
27.   Wyckoff, J.B., Insel, L., Khazaie, K., Lichtner, R.B., Condeelis, J.S. and J.E. Segall (1998) Suppression of ruffling by EGF in chemotactic cells.  Exp. Cell Res. 242:100-109.
28.   Bailly, M., Macaluso, F., Cammer, M., Chan, A., Segall, J.E., and J.S. Condeelis.  (1999) Relationship between Arp2/3 complex and the barbed ends of actin filaments at the leading edge of carcinoma cells after EGF stimulation.  J. Cell Biol. 145:331-345.
29.   Hill, K., Welti, S., Yu, J., Murray, J.T., Yip, S., Condeelis, J.S., Segall, J.E., Backer, J.M. (2000) Specific requirement for the p85-p110alpha PI 3-kinase during EGF-stimulated actin nucleation in breast cancer cells. J. Biol. Chem. 275:3741-3744.
30.   Chan,A.Y.,  Bailly,M.,  Zebda,N.,  Segall,J.E, and J.S. Condeelis (2000) Role of cofilin in epidermal growth factor-stimulated actin polymerization and lamellipod protrusion.  J Cell Biol. 148:531-542. 
31.   Wyckoff, J.B.,Jones, J.G., Condeelis, J. C., and J E. Segall (2000) A critical step in metastasis: In vivo analysis of intravasation at the primary tumor.  Cancer Res. 60:2504-2511.  PubMed PMID: 10811132.
32.   Wyckoff, J.B., Segall, J.E. and Condeelis, J.C. (2000) The collection of the motile population of cells from a living tumor. Cancer Res. 60:5401-5404. 
33.   Bailly,M. , Wyckoff,J.B., Bouzahzah, B., Hammerman,R., Sylvestre,V., Cammer,M., Pestell,R.G., and J. E. Segall (2000) Distribution of the EGF receptor in chemotaxing adenocarcinoma cells. Mol. Biol. Cell. 11:3873-3883. 
34.   Hill, K.M., Huang, Y, Yip, S.-C., Yu, J., Segall, J.E., and J.M. Backer. (2001) N-terminal domains of the class IA phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling.  J. Biol. Chem.  276:16374-16378. 
35.   Bailly, M., Ichetovkin, I., Grant, W., Zebda, N., Machesky, L.M., Segall, J.E., and J. Condeelis (2001)  The F-actin side binding activity of the Arp 2/3 complex is essential for actin nucleation and lamellipod extension.  Curr. Biol. 11: 620-625.
36.   Bouzahzah, B., Albanese, C., Ahmed, F., Pixley, F., Lisanti, M. P, Segall, J.E., Condeelis, J., Joyce, J., Minden, A, Der, C.J., Chan, A., Symons, M. and R. G. Pestell. (2001) Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis Through Distinguishable Pathways.  Mol. Med. 7: 816–830.
37.   Wang, W., Wyckoff, J.B., Frohlich, V.C., Oleynikov, Y., Huttelmaier, S., Zavadil, J., Cermak, L., Bottinger, E.P., Singer, R.H., White, J.G., Segall, J.E., and J.S. Condeelis.  (2002) Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 62:6278-88.
38.   Vallier, L.G., Segall, J.E., and M. Snyder. (2002) The alpha-factor receptor C-terminus is important for mating projection formation and orientation in Saccharomyces cerevisiae.  Cell Motil Cytoskeleton 53:251-66. PubMed PMID: 12378535
39.   Butty, A.C., Perrinjaquet, N., Petit, A., Jaquenoud, M., Segall, J.E., Hofmann, K., Zwahlen, C., and M. Peter.  (2002)  A positive feedback loop stabilizes the guanine-nucleotide exchange factor Cdc24 at sites of polarization.  EMBO J 21:1565-76. PubMed PMID: 11927541; PubMed Central PMCID: PMC125953.
40.   Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, Miyazaki J, Jones J, Pollard JW, Condeelis JS, Segall JE. (2002) GFP Expression in the Mammary Gland for Imaging of Mammary Tumor Cells in Transgenic Mice. Cancer Res. 62:7166-9. PubMed PMID: 12499251.
41.   Wang W, Wyckoff JB, Wang Y, Bottinger EP, Segall JE, Condeelis JS. (2003) Gene expression analysis on small numbers of invasive cells collected by chemotaxis from primary mammary tumors of the mouse.  BMC Biotechnol. 3:13-25.
42.   Kempiak, S., Yip, J.-L., Backer, J., and J. E. Segall (2003) Local signaling by the EGF receptor. J. Cell Biol.162:781-787.  PubMed PMID: 12952932; PubMed Central PMCID: PMC2172819.
43.   Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004 ) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64:7022-9.
44.   Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, Singer RH, Segall JE, Condeelis JS. (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors.  Cancer Res. 64:8585-94.
45.   Kempiak SJ, Yamaguchi H, Sarmiento C, Sidani M, Ghosh M, Eddy RJ, Desmarais V, Way M, Condeelis JS, Segall JE (2005) J. Biol. Chem.  280:5836-5842.
46.   Goswami S, Sahai E, Wyckoff J, Cox D, Pixley F, Stanley ER, Segall JE, Condeelis, J (2005)  Macrophages promote the invasion of carcinoma cells in vitro via a paracrine loop.  Cancer Res. 65:5278-83.
47.   Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, Segall J, Eddy R, Miki H, Takenawa T, Condeelis J. (2005)  Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin.  J Cell Biol. 168(3):441-52.
48.   Sahai E, Wyckoff J, Philippar U, Segall JE, Gertler F, Condeelis J.  (2005) Simultaneous imaging of GFP, CFP and collagen in tumors in vivo using multiphoton microscopy. BMC Biotechnol. 5:14-22.
49.   Soon L, Mouneimne G, Segall J, Wyckoff J, Condeelis J. (2005) Description and characterization of a chamber for viewing and quantifying cancer cell chemotaxis. Cell Motil Cytoskeleton. 62(1):27-34.
50.   Xue C, Wyckoff J, Liang F,Sidani M, Violini S, Tsai K-L, Zhang Z-Y, Sahai E, Condeelis J, Segall JE (2006) EGF receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis.  Cancer Res. 66:192-7
51.   Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, TsaiK-L, Kim M,  Locker J, Zhang Z-Y, Segall JE (2006 ) ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res. 66: 1418-1426.
52.   Chen S, Segall JE (2006) EppA, a putative substrate of DdERK2, regulates cyclic AMP relay and chemotaxis in Dictyostelium discoideum. Eukaryot Cell. 5:1136-46. PubMed PMID: 16835457; PubMed Central PMCID: PMC1489283.
53.   Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J.  (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.  Cancer Res. 67:2649-56.
54.   Wang W, Wyckoff JB, Goswami S, Wang Y, Sidani M, Segall JE, Condeelis JS. (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors.  Cancer Res. 67:3505-11.
55.   Pu J, McCaig CD, Cao L, Zhao Z, Segall JE, Zhao M. (2007) EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells.  J Cell Sci. 120 :3395-403. 
56.   Kedrin D, Gligorijevic B, Wyckoff J, Verkhusha VV, Condeelis J, Segall JE, van Rheenen J (2008) Intravital imaging of metastasis through an orthotopic Mammary Imaging Window.  Nature Methods. Nature Methods. 5:1019-21
57.   Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Stanley ER, Cox D, Muller WJ, Pollard JW, van Rooijen N, Segall JE (2009) EGF/CSF-1 Induced Breast Cancer Cell Invasion is Triggered by Heregulin Beta 1 and CXCL12. Cancer Res. 69:3221-7.
58.   Kedrin D, Wyckoff JB, Hynes NE, Arteaga CL, Segall JE (2009) ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin. Cancer Res. 15: 3733-9.
59.   Gligorijevic B, Kedrin D, Segall JE, Condeelis J, van Rheenen J. (2009) Dendra2 photoswitching through the Mammary Imaging Window.  J Vis Exp. 28:1278.  
60.   Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM. (2009) Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.  Cancer Res. 69(23):8868-76. 
61.   Piatkevich KD, Hulit J, Subach OM, Wu B, Abdulla A, Segall JE, Verkhusha VV. (2010) Monomeric red fluorescent proteins with a large Stokes shift. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5369-74.
62.   Hernandez L, Magalhaes MA, Coniglio SJ, Condeelis JS, Segall JE: Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast cancer research : BCR 2011, 13(6):R128.
63.   Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, Ferrick N, Segall J, Pollard JW, Kitsis RN: Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer research 2011, 71(24):7705-7715.
64.   Loudig O, Brandwein-Gensler M, Kim RS, Lin J, Isayeva T, Liu C, Segall JE, Kenny PA, Prystowsky MB: Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma. Human pathology 2011, 42(12):1911-1922.
65.   Boimel PJ, Cruz C, Segall JE: A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer. Genomics 2011, 98(3):164-172.
66.   Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE et al: Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. Journal of cell science 2011, 124(Pt 13):2120-2131.
67.   Smirnova T, Adomako A, Locker J, Van Rooijen N, Prystowsky MB, Segall JE: In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages. The American journal of pathology 2011, 178(6):2857-2865.
68.   Henkels KM, Farkaly T, Mahankali M, Segall JE, Gomez-Cambronero J: Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3). Journal of molecular biology 2011, 408(5):850-862.
69.   Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park HI, Coniglio SJ, Patel P, Qian BZ, Stanley ER, Bresnick AR et al: Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast cancer research : BCR 2012, 14(1):R23.
70.   Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE: Microglial stimulation of glioblastoma invasion involves EGFR and CSF-1R signaling. Molecular medicine (Cambridge, Mass) 2012.
71.   Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R et al: Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. The American journal of pathology 2012, 180(3):917-928.
72.   Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS et al: Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 2012, 31(6):706-71.
73.   Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA, Segall JE. (2012). Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PloS one. 7(4):e35569.  PMID: 22530051 / PMCID: PMC3329481.
74.   Ishihara D, Dovas A, Hernandez L, Pozzuto M, Wyckoff J, Segall JE, Condeelis JS, Bresnick AR, Cox D. (2013) Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Rep. 4(3):429-36. PubMed PMID: 23911287.
75.   Zhou ZN, Sharma V, Beaty B, Roh-Johnson M, van Rooijen N, Kenny P, Wiley S, Condeelis J, Segall JE.  (2013) Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.  Oncogene 33(29):3784-93.
76.   Ishihara D, Dovas A, Hernandez L, Pozzuto M, Wyckoff J, Segall JE, Condeelis JS, Bresnick AR, Cox D. WASp is required for tumor associated macrophages to promote breast carcinoma cell invasion and metastasis. Cell Reports. 2013 4:429-36.
77.   Qian X, Hulit J, Suyama K, Eugenin EA, Belbin TJ, Loudig O, Smirnova T, Zhou ZN, Segall J, Locker J, Phillips GR, Norton L, Hazan RB. p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis. Oncogene. 2013 May 2;32(18):2292-303.
78.   Kim S, Yao J, Suyama K, Qian X, Qian BZ, Bandyopadhyay S, Loudig O, De Leon-Rodriguez C, Zhou ZN, Segall J, Macian F, Norton L, Hazan RB. Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis. Cancer Res. 2014 Jul 15;74(14):3695-706.
79.   Jimenez L, Sharma VP, Condeelis J, Harris T, Ow TJ, Prystowsky MB, Childs G, Segall JE. MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma. Arch Pathol Lab Med. 2015 Nov;139(11):1349-61. doi: 10.5858/arpa.2014-0471-OA. Epub 2015 Jul 14.  PubMed PMID: 26172508; PubMed Central PMCID: PMC4628565
80.   Jimenez L, Lim J, Burd B, Harris TM, Ow TJ, Kawachi N, Belbin TJ, Angeletti R, Prystowsky MB, Childs G, Segall JE. miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. Am J Pathol. 2017 Jul;187(7):1523-1536. doi: 10.1016/j.ajpath.2017.02.019. Epub 2017 May 10. PubMed PMID: 28499703; PubMed Central PMCID: PMC5500828
81.   Jayakar SK, Loudig O, Brandwein-Gensler M, Kim RS, Ow TJ, Ustun B, Harris TM, Prystowsky MB, Childs G, Segall JE, Belbin TJ. Apolipoprotein E Promotes Invasion in Oral Squamous Cell Carcinoma. Am J Pathol. 2017 Oct;187(10):2259-2272. doi: 10.1016/j.ajpath.2017.06.016. Epub 2017 Jul 24. PubMed PMID: 28751006; PubMed Central PMCID: PMC5762938.
82.   Donnelly SK, Cabrera R, Mao SPH, Christin JR, Wu B, Guo W, Bravo-Cordero JJ, Condeelis JS, Segall JE, Hodgson L. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017 Dec 4;216(12):4331-4349. doi: 10.1083/jcb.201704048. Epub 2017 Oct 23. PubMed PMID: 29061650; PubMed Central PMCID: PMC5716284. 
83. Suyama K, Yao J, Liang H, Benard O, Loudig OD, Amgalan D, McKimpson WM,Phillips GR, Segall J, Wang Y, Fineberg S, Norton L, Kitsis RN, Hazan RB. An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer Res. 2018 Jan 1;78(1):103-114. doi: 10.1158/0008-5472.CAN-15-1462. Epub 2017 Oct 16. PubMed PMID: 29038347.  
84. Cabrera RM, Mao SPH, Surve CR, Condeelis JS, Segall JE. A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration. Breast Cancer Res. 2018 Apr 10;20(1):24. doi: 10.1186/s13058-018-0960-8. PubMed PMID: 29636067; PubMed Central PMCID: PMC5894135. 
85. Mao SPH, Park M, Cabrera RM, Christin JR, Karagiannis GS, Oktay MH, Zaiss DMW, Abrams SI, Guo W, Condeelis JS, Kenney PA, Segall JE. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.  Breast Cancer Res. 2018 Oct 26;20(1):131. doi: 10.1186/s13058-018-1057-0. PubMed PMID: 30367629; PubMed Central PMCID: PMC6203982. 
86. Suh YJ, Hall MS, Huang YL, Moon SY, Song W, Ma M, Bonassar LJ, Segall JE, Wu M. Glycation of collagen matrices promotes breast tumor cell invasion. Integr Biol (Camb). 2019 May 1. pii: zyz011. doi: 10.1093/intbio/zyz011. PubMed PMID: 31041443. 
87. Carter KP, Hanna S, Genna A, Lewis D, Segall J E, Cox D.  Macrophages enhance 3D invasion in a breast cancer cell line by induction of tumor cell tunneling nanotubes. Cancer Reports. 2019 Dec;2(6):e1213. doi: 10.1002/cnr2.1213. Epub 2019 Aug 28. PMID: 32467880; PMCID: PMC7254960.  
88. Dalaka E, Kronenberg NM, Liehm P, Segall JE, Prystowsky MB, Gather MC. Direct measurement of vertical forces shows correlation between mechanical activity and proteolytic ability of invadopodia. Sci Adv. 2020 Mar 11;6(11):eaax6912. doi:10.1126/sciadv.aax6912. PMID: 32195338; PMCID: PMC7065877. 
89. Huang YL, Ma Y, Wu C, Shiau C, Segall JE, Wu M. Tumor spheroids under perfusion within a 3D microfluidic platform reveal critical roles of cell-cell adhesion in tumor invasion. Sci Rep. 2020 Jun 15;10(1):9648. doi:10.1038/s41598-020-66528-2. PMID: 32541776; PMCID: PMC7295764.
 90. Huang YL, Shiau C, Wu C, Segall JE, Wu M. The architecture of co-culture spheroids regulates tumor invasion within a 3D extracellular matrix. Biophys Rev Lett. 2020 Sep;15(3):131-141. doi: 10.1142/s1793048020500034. Epub 2020 Jul 13. PMID: 33033500; PMCID: PMC7540657.
91. Gadsden NJ, Fulcher CD, Li D, Shrivastava N, Thomas C, Segall JE, Prystowsky MB, Schlecht NF, Gavathiotis E, Ow TJ. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Mol Cancer Res. 2021 May;19(5):862-873. doi:10.1158/1541-7786.MCR-20-0915. Epub 2021 Jan 25. PMID: 33495400; PMCID: PMC8314015. 
92. Huelsemann M, Sanchez C, Verkhusha PV, Des Marais V, Mao SPH, Donnelly SK, Segall JE, Hodgson L. TC10 regulates breast cancer invasion and metastasis bycontrolling membrane type-1 matrix metalloproteinase at invadopodia. Commun Biol. 2021 Sep 16;4(1):1091. doi: 10.1038/s42003-021-02583-3. PMID: 34531530. 
93. Coniglio SJ, Segall JE. Microglial-stimulation of glioma invasion involves the EGFR ligand amphiregulin. PLoS One. 2021 Nov 29;16(11):e0260252. doi: 10.1371/journal.pone.0260252. PMID: 34843542; PMCID: PMC8629255. 
94. Cheung BCH, Hodgson L, Segall JE, Wu M. Spatial and temporal dynamics of RhoA activities of single breast tumor cells in a 3D environment revealed by a machine learning-assisted FRET technique. Exp Cell Res. 2022 Jan 15;410(2):112939. doi: 10.1016/j.yexcr.2021.112939. Epub 2021 Nov 20. PMID: 34813733; PMCID: PMC8714707. 
95. Sharma VP, Tang B, Wang Y, Duran CL, Karagiannis GS, Xue EA, Entenberg D, Borriello L, Coste A, Eddy RJ, Kim G, Ye X, Jones JG, Grunblatt E, Agi N, Roy S, Bandyopadhyaya G, Adler E, Surve CR, Esposito D, Goswami S, Segall JE, Guo W, Condeelis JS, Wakefield LM, Oktay MH. Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination. Nat Commun. 2021 Dec 15;12(1):7300. doi: 10.1038/s41467-021-27308-2. PMID: 34911937; PMCID: PMC8674234. 
96. Suh YJ, Pandey M, Segall JE, Wu M. Tumor spheroid invasion in epidermal growth factor gradients revealed by a 3D microfluidic device. Phys Biol. 2022 Mar 10;19(3). doi: 10.1088/1478-3975/ac54c7. PMID: 35158347.
  
B.  Books, Chapters in Books, and Review Articles
 1.      Segall, J.E. and G. Gerisch (1989) Genetic approaches to cytoskeleton function and the control of cell motility.  Curr. Op. Cell Biol.: Cytoplasm and Cell Motility.  1:44-50. PubMed PMID: 2560931.
2.      Gerisch, G., Segall, J.E. and E. Wallraff. (1989) Isolation and Behavioral Analysis of Mutants Defective in Cytoskeletal Proteins.  Cell Motility and the Cytoskeleton.  14:75-79.  PubMed PMID: 2684431.
3.      Segall, J. E. (1990) Mutational Studies of Amoeboid Chemotaxis using Dictyostelium discoideum.  In: Biology of the Chemotactic Response, (J. Armitage and J. Lackie, eds.)  Cambridge University Press, Cambridge, pp 241--272.
4.      Jones, J., Segall, J.E. and J. Condeelis. (1991) Molecular analysis of amoeboid chemotaxids:  parallel observation in amoeboid phagocytes and metastatic tumor cells.  In Cytokines and Cell Motility (I. Goldberg and E. Rosen, eds.) Birkhauser Verlag, New York.  PubMed PMID: 1833224.
5.      Manson, M.D., and J.E. Segall (1992) Chemotaxis.  In The Encyclopedia of Microbiology (J. Lederberg, ed.) Academic Press, San Diego.
6.      Condeelis, J., Jones, J., and J. E. Segall (1992) Chemotaxis of metastatic tumor cells: clues to mechanisms from the Dictyostelium paradigm.  Cancer and Metastasis Reviews 11:55-68.
7.      Mann, S. P. Devreotes, S. Eliott, K. Jermyn, A. Kuspa, M. Fechheimer, R. Furukawa, C. Parent, J. Segall, G. Shaulsky, P. Vardy, J. Williams, and R. Firtel. (1994) Cell biological, molecular genetic, and biochemical methods to examine Dictyostelium.  In: "Cell Biology:  A Laboratory Handbook" (ed J. Celis), Academic Press 1:412-451.
8.      Cammer, M., Wyckoff, J. and J.E. Segall (1997) Computer-assisted analysis of single cell motility.  In: Basic Cell Culture Protocols (eds. J.M. Walker and J.W. Pollard), Methods in Molecular Biology, 75:459-470.
9.      Zigmond, S.H., Foxman, E.F. and J.E. Segall (1998) Chemotaxis Assays for Eukaryotic Cells. In: Current Protocols in Cell Biology (eds) Bonifacino, J.S., et al.  New York, John Wiley & Sons. (in press).
10.   Bailly, M. Condeelis, J. and Segall, J.E. (1998) Chemoattractant-induced lamellipod extension.  Microscopy Research and Technique. 43:433-443
11.   Segall, J.E. (1999) Cell Polarization: Chemotaxis gets cracking. Current Biology  9:R46-R48.
12.   Pestell, R.G., Albanese, C., Reutens , A.T., Segall,  J.E., Lee, R.J., and Arnold, A. (1999) The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20:501-34.
13.   Condeelis, J.S., Wyckoff, J., and J. E. Segall (2000) Imaging of cancer invasion and metastasis using green fluorescent protein.  Eur. J. Cancer 36:1671-1680.
14.   Condeelis. J.S., Wyckoff, J.B., Bailly, M.,  Pestell, R., Lawrence,D., Backer, J., and Jeffrey E. Segall (2001) Lamellipodia in invasion.  Sem. Canc. Biol. 11:119-128.
15.   Condeelis, J. and J.E. Segall (2003) Intravital imaging of cell movements in tumors.  Nat. Rev. Canc. 3:921-930.
16.   Condeelis J, Song X, Backer J, Wyckoff J and JE Segall (2003) Chemotaxis of cancer cells during invasion and metastasis. In: Cell Motility:  from molecules to organisms. (Editors: Anne Ridley, Michelle Peckham, Peter Clark) Wiley & Sons. 175-188.
17.   Kempiak, S.J. and J.E. Segall (2004) Stimulation of cells using EGF-coated magnetic beads. Sci STKE. 218:pl1.
18.   Meili, R., Richard A. Firtel, R.A.  and J. E. Segall. (2004) Molecular Mechanisms of Chemotaxis in Amoebae.  In: Chemotaxis (editor Michael Eisenbach) U.K.,  Imperial College Press. 253-294.
19.   Bozzaro, S., Fisher P.R., Loomis, W., Satir, P. and J. E. Segall (2004) Guenther Gerisch and Dictyostelium, the microbial model for ameboid motility and multicellular morphogenesis.  Trends Cell Biol. 14:585-9.
20.   Wyckoff J, Segall JE, and J Condeelis (2005) “Chapter 22:  Single cell imaging in animal tumors in vivo” in Live Cell Imaging: a Laboratory Manual, Eds.:  D.L. Spector and R.D. Goldman.  CSHL.  Cold Spring Harbor, NY. Pp. 409 - 422.
21.   Wang W, Goswami S, Sahai E, Wyckoff JB, Segall JE, Condeelis JS. (2005) Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 15:138-45.
22.   Ingman, W., Wyckoff J, Xue C, Lin EY, Wang W, Goswami S, Pollard JW, Condeelis J, and JE Segall (2005) Imaging Invasion and Metastasis In vivo.  In: Cell Motility in Cancer Invasion and Metastasis (editor Alan Wells), Kluwer Academic Publishers.
23.   Condeelis J, Singer R, Segall JE (2005) The great escape: When cancer cells hijack the genes for chemotaxis and motility.  Ann. Rev. Cell Dev. Biol. 21: 695-718.
24.   Sidani M, Wyckoff J, Xue C, Segall JE, Condeelis J. (2006) Probing the microenvironment of mammary tumors using multiphoton microscopy.  J Mammary Gland Biol Neoplasia. 11:151-63.
25.   Wyckoff JB, Condeelis J, Segall JE (2006) Growth factor receptors – doing more than just stimulating tumor growth?  BIF Futura. 21:219-223.
26.   Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE (2007)  Imaging of tumor cell movement in vivo.  Current Protocols in Cell Biology.  19.7.1 – 19.7.17.
27.   Smirnova T, Segall JE (2007) Amoeboid chemotaxis: future challenges and opportunities.  Cell Adhesion and Migration. 1:4, 1-6.
28.   Kedrin D, van Rheenen J, Hernandez L, Condeelis J, Segall JE (2007) Cell motility and cytoskeletal regulation in invasion and metastasis.  J. Mam. Gland Biol. Neoplasia. 12: 143-52.
29.   Symons M and Segall JE (2009) Rac and Rho driving tumor invasion: who’s at the wheel? Genome Biology.10:213.1 - .4.
30.   Hernandez L, Smirnova T, Wyckoff J, Condeelis J, Segall JE (2009) In vivo assay for tumor cell invasion.  Methods in Molecular Biology. 571:227-38
31.   Zhou ZN, Boimel PJ, Segall JE: Tumor-stroma: In vivo assays and intravital imaging to study cell migration and metastasis. Drug discovery today Disease models 2011, 8(2-3):95-112.
32.   Wyckoff J, Gligorijevic B, Entenberg D, Segall J, Condeelis J: The in vivo invasion assay: preparation and handling of collection needles. Cold Spring Harbor protocols 2011, 2011(10):1232-1234.
33.   Wyckoff J, Gligorijevic B, Entenberg D, Segall J, Condeelis J: High-resolution multiphoton imaging of tumors in vivo. Cold Spring Harbor protocols 2011, 2011(10):1167-1184.
34.   Locker J, Segall JE: Breast cancer: the matrix is the message. The American journal of pathology 2011, 178(3):966-968.
35.   Childs G, Segall JE. (2012). Twists and turns of invasion. Nature cell biology. 14(4):337-9.  PMID: 22469829.
36.   Friedl P, Locker J, Sahai E, Segall JE. (2012) Classifying collective cancer cell invasion. Nat Cell Biol. 14(8):777-83. PubMed PMID: 22854810.
37.   Hulit J, Kedrin D, Gligorijevic B, Entenberg D, Wyckoff J, Condeelis J, Segall JE. (2012). The use of fluorescent proteins for intravital imaging of tumor cell invasion. In: In vivo cellular imaging using fluorescent proteins: methods and protocols. Hoffman, Robert M. (Ed.)  Methods in Molecular Biology, Vol. 872. Humana Press, pp 15 – 30.
38.   Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. (2013) Imaging tumor cell movement in vivo.  Curr Protoc Cell Biol. Chapter 19:Unit19.7.
39.   Coniglio S, Segall JE. Molecular mechanism of microglia stimulated glioblastoma invasion.  Matrix Biology.  2013 32:372-80.
40.   Jimenez L, Jayakar SK, Ow TJ, Segall JE. Mechanisms of Invasion in Head and Neck Cancer. Arch Pathol Lab Med. 2015 Nov;139(11):1334-48. doi: 10.5858/arpa.2014-0498-RA. Epub 2015 Jun 5. Review. PubMed PMID: 26046491.
41.   Coniglio S, Miller I, Symons M, Segall JE. Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion. J Vis Exp. 2016 Oct 20;(116). doi: 10.3791/53990. PubMed PMID: 27805587.
42.   Chiang SP, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C1-C14. doi: 10.1152/ajpcell.00238.2015. Epub 2016 Apr 13. Review. PubMed PMID: 27076614; PubMed Central PMCID: PMC4967137.
43.   Huang YL, Segall JE, Wu M. Microfluidic modeling of the biophysical microenvironment in tumor cell invasion. Lab Chip. 2017 Sep 26;17(19):3221-3233.  doi: 10.1039/c7lc00623c. PubMed PMID: 28805874.
44.   Carter KP, Segall JE, Cox D.  Microscopic Methods for Analysis of Macrophage-Induced Tunneling Nanotubes. Meth. Mol. Biol. Methods Mol Biol. 2020;2108:273-279. doi: 10.1007/978-1-0716-0247-8_23. PMID: 31939188; PMCID: PMC7594733.

Is Open Scheduling

Off

Steven C. Almo

Read more about Steven C. Almo

Steven C. Almo

https://assets.montefioreeinstein.org/profiles/images/Almo_Steve_2x.jpeg

Faculty

Expert

First Name

Steven

Last Name

Almo

Faculty ID

7091

Patient Type

Adult

Department

einstein-dept-biochemistry

steve.almo@einsteinmed.edu

Phone

718-430-2746

Titles

Type

Academic

Department

Department of Biochemistry

Department Link

Rank

Professor

Type

Administrative

Title

Chair, Department of Biochemistry

Type

Administrative

Title

Wollowick Family Foundation Chair in Multiple Sclerosis and Immunology

Type

Administrative

Title

Director, Einstein Macromolecular Therapeutics Developmental Facility

Type

Administrative

Title

Co-Leader, Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program

Tags

me-patientcare-cancer-research-therapeutics

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Forchheimer Building

Room

308

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

Our laboratory is interested in the development and application of strategies and technologies that enable the high-throughput/large-scale exploration of biological function. These efforts typically take advantage of automation and robotics to achieve the efficiencies and speed required to realize the desired rates of data generation and discovery. This cutting-edge infrastructure has been applied to a number of important biomedical areas to achieve new understanding and new therapeutic opportunities.
Our work on the large-scale annotation of enzyme function is helping to define the metabolic repertoire that exists in Nature and is providing new insights into the contributions of the gut microbiome to human health, the realization of new chemical processes for industry, and expanding our understanding of critical environmental issues, including global nutrient cycles and the evolution of complex microbial communities. Our high-resolution structural and functional analysis of the mammalian immune system has resulted in unprecedented understanding of the molecular mechanisms that control immunity and are guiding the development of novel strategies and reagents (e.g., biologics) for the treatment of infectious diseases, autoimmune diseases and cancers.

Specialties

Expert Tags

Areas of Expertise

Biochemistry

Drug Discovery

Expert Summary

Dr. Steven Almo is an internationally recognized leader in the field of structural biology. His lab uses high-resolution X-ray crystallography to determine the shapes and structures of proteins to better understand their function and help develop new drugs. The goal is to make immunotherapy treatments that more precisely and effectively treat a variety of cancers while causing far fewer side effects than current therapies. 
Dr. Almo’s large-scale work on enzyme function has provided insights on both the gut microbiome’s contributions to human health and new chemical processes for industry. His research also has expanded the understanding of critical environmental issues, including global nutrient cycles and the evolution of complex microbial communities.
He is a member of the American Society for Cell Biology and the American Crystallographic Association. He has served on NIH study sections and review panels, on the American Cancer Society’s Peer Review Committee on Cancer Drug Development, and on the editorial board of the International Archives of Allergy and Immunology.

Research Profile

https://einsteinmed.edu/faculty/7091/Steven-Almo

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/054be1ff-29d5-459e-90e7-4f3851a82…

Selected Publications

Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, Histed A, Zhao F, Moreta M, Ruthardt P, Hulot S, Nelson A, Kraemer LD, Beal DR, Witt L, Ryabin J, Soriano J, Haydock M, Spaulding E, Ross JF, Kiener PA, Almo S, Chaparro R, Seidel R, Suri A, Cemerski S, Pienta KJ, Simcox ME. (2020) "CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies." Clin Cancer Res. 26(8), 1953-1964. PMID:31964784.
Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA. (2020) "A metabolic pathway for bile acid dehydroxylation by the gut microbiome." Nature 582(7813), 566-570. PMC7319900.
Liu W, Garrett SC, Fedorov EV, Ramagopal UA, Garforth SJ, Bonanno JB, Almo SC. (2019) "Structural Basis of CD160:HVEM Recognition." Structure 27(8), 1286-1295.e4. PMC7477951.
Gizzi AS, Grove TL, Arnold JJ, Jose J, Jangra RK, Garforth SJ, Du Q, Cahill SM, Dulyaninova NG, Love JD, Chandran K, Bresnick AR, Cameron CE, Almo SC.  (2018) “A naturally occurring antiviral ribonucleotide encoded by the human genome.” Nature 558, 610-614.  PMC6026066.
Ghosh A, Ramagopal UA, Bonanno JB, Brenowitz M, Almo SC. (2018) “Structures of the L27 Domain of Disc Large Homologue 1 Protein Illustrate a Self-Assembly Module.” Biochemistry 57, 1293-1305. PMC6568269.
Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, Deshpande S, Korman AJ, Almo SC. (2017) “Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.”  Proc Natl Acad Sci U S A. 114, E4223-E4232.  PMC5448203.
Lázár-Molnár E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC. (2017) “Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.”  EBioMedicine. 17, 30-44. PMC5360572. 
Samanta D, Guo H, Rubinstein R, Ramagopal UA, Almo SC. (2017) “Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2.” Mol Immunol. 81, 51-159. PMC5220579.
Liu W, Ramagopal U, Cheng H, Bonanno JB, Toro R, Bhosle R, Zhan C, Almo SC. (2016) “Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.” Structure 24, 2016-2023. PMID:27806260.
Yadava U, Vetting MW, Al Obaidi N, Carter MS, Gerlt JA, Almo SC. (2016) “Structure of an ABC transporter solute-binding protein specific for the amino sugars glucosamine and galactosamine.” Acta Crystallogr F Struct Biol Commun. 72, 467-472. PMC4909247.
Liu W, Vigdorovich V, Zhan C, Patskovsky Y, Bonanno JB, Nathenson SG, Almo SC. (2015) “Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM.” Mol Biotechnol. 57, 914-922. PMID:26202493.
Kim J, Xiao H, Koh J, Wang Y, Bonanno JB, Thomas K, Babbitt PC, Brown S, Lee YS, Almo SC. (2015) “Determinants of the CmoB carboxymethyl transferase utilized for selective tRNA wobble modification.” Nucleic Acids Res. 43, 4602-4613.  PMC4482062.
 Vetting MW, Al-Obaidi N, Zhao S, San Francisco B, Kim J, Wichelecki DJ, Bouvier JT, Solbiati JO, Vu H, Zhang X, Rodionov DA, Love JD, Hillerich BS, Seidel RD, Quinn RJ, Osterman AL, Cronan JE, Jacobson MP, Gerlt JA, Almo SC. (2015) “Experimental strategies for functional annotation and metabolism discovery: targeted screening of solute binding proteins and unbiased panning of metabolomes.” Biochemistry 54, 909-931. PMC4310620.
Samanta D, Almo SC. (2015) “Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity.” Cell Mol Life Sci. 72, 645-658. PMID: 25326769.
Liu W, Zhan C, Cheng H, Kumar PR, Bonanno JB, Nathenson SG, Almo SC. (2014) “Mechanistic basis for functional promiscuity in the TNF and TNF receptor superfamilies: structure of the LIGHT:DcR3 assembly.” Structure 22, 1252-1262.  PMC4163024.
Bandaranayake AD, Almo SC. (2014) “Recent advances in mammalian protein production.” FEBS Lett. 588, 253-260. PMC3924552.
Kim J, Xiao H, Bonanno JB, Kalyanaraman C, Brown S, Tang X, Al-Obaidi NF, Patskovsky Y, Babbitt PC, Jacobson MP, Lee YS, Almo SC. (2013) “Structure-guided discovery of the metabolite carboxy-SAM that modulates tRNA function.” Nature 498, 123-126.  PMC3895326.
Kim J, Almo SC. (2013) “Structural basis for hypermodification of the wobble uridine in tRNA by bifunctional enzyme MnmC.” BMC Struct Biol. 13:5. PMC3648344.
Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC. (2013) “Structure and T cell inhibition properties of B7 family member, B7-H3.” Structure 21, 707-717. PMC3998375.
Soniat M, Sampathkumar P, Collett G, Gizzi AS, Banu RN, Bhosle RC, Chamala S, Chowdhury S, Fiser A, Glenn AS, Hammonds J, Hillerich B, Khafizov K, Love JD, Matikainen B, Seidel RD, Toro R, Rajesh Kumar P, Bonanno JB, Chook YM, Almo SC. (2013) “Crystal structure of human Karyopherin β2 bound to the PY-NLS of Saccharomyces cerevisiae Nab2.” J Struct Funct Genomics 14, 31-35. PMC3681870.
Sampathkumar P, Kim SJ, Upla P, Rice WJ, Phillips J, Timney BL, Pieper U, Bonanno JB, Fernandez-Martinez J, Hakhverdyan Z, Ketaren NE, Matsui T, Weiss TM, Stokes DL, Sauder JM, Burley SK, Sali A, Rout MP, Almo SC. (2013) “Structure, dynamics, evolution, and function of a major scaffold component in the nuclear pore complex.” Structure 21, 560-571. PMC3755625.

Is Open Scheduling

Off

John S. Condeelis

Read more about John S. Condeelis

John S. Condeelis

https://assets.montefioreeinstein.org/profiles/images/Condeelis_John_PhD_2x.jpg

Faculty

Expert

First Name

John

Last Name

Condeelis

Faculty ID

6712

Patient Type

Adult

Department

einstein-dept-cell-biology

einstein-dept-surgery

john.condeelis@einsteinmed.edu

Phone

718-430-2718

Titles

Type

Academic

Department

Department of Cell Biology

Department Link

Rank

Professor

Tags

me-patientcare-cancer-research-cdtmi

me-patientcare-cancer-research-cdtmi-members

Type

Academic

Department

Department of Surgery

Rank

Professor

Type

Administrative

Title

The Judith and Burton P. Resnick Chair in Translational Research

Type

Administrative

Title

Scientific Director, Analytical Imaging Facility

Type

Administrative

Title

Director, Integrated Imaging Program for Cancer Research

Type

Administrative

Title

Director, Basic and Translational Research, Department of Surgery

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Forchheimer Building

Room

602

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

John Condeelis' research interests are in optical physics, cell biology and biophysics, cancer biology and mouse models of cancer. He and his collaborators developed the multiphoton imaging technology and animal models used to identify invasion and dissemination micro-environments in breast, pancreas and lung carcinoma. Integration of intravital multiphoton imaging with computational /systems analysis of living breast tumors identified the dominant tumor cell phenotypes contributing to invasion and dissemination during metastasis. This led to the discovery and verification of the paracrine interaction between tumor cells and macrophages in vivo, the role of macrophages in the migration of tumor cells during HGF-dependent tumor cell streaming to blood vessels and the mechanism of tumor cell dissemination from primary tumors via TMEM (Tumor MicroEnvironment of Metastasis) doorways to distant metastatic sites, and from those metastatic sites. Based on these results, cell collection techniques, including the in vivo invasion assay were developed for the collection of migrating and disseminating macrophages and tumor cells. This led to the discovery of the mouse and human invasion signatures, and the TMEM doorway, MenaCalc and MenaINV markers for assessing risk of metastasis and prediction of response in breast cancer patients to both chemotherapy, and receptor tyrosine kinase and tyrosine kinase inhibitors used to suppress metastasis.
He also helped lead the effort to develop a TMEM-activity-MRI for use in standard of care MRI prognosis of breast cancer patients. He is one of the founding co-directors of the Integrated Imaging Program dedicated to the integration and validation of clinical imaging platforms, including digital pathology, with high resolution optical imaging in the Gruss Lipper Biophotonics Center. He has authored more than 350 scientific papers on various aspects of his research.

Research Areas

Interests are in optical physics, cell biology and biophysics, and cancer biology. Applications of interests are in development of the multiphoton imaging technology used to identify dissemination microenvironments in metastatic tumors.

Specialties

Cancer

Basic Science

Expert Tags

Tumor Microenvironment

Metastasis

Imaging

Areas of Expertise

Multiphoton imaging

Optical microscopy

Biomedical technologies

Tumor microenvironment

Expert Summary

Dr. Condeelis is a pioneer in developing microscope techniques for use in “intravital imaging” – observing the behavior of cells in living animals. His work has led to a clinical test of biopsy tissue to determine whether a woman’s breast cancer will spread (metastasize), which could help determine treatment. Because of the test’s success, Dr. Condeelis and colleagues have licensed the patent rights to a biotech firm, which is developing the tissue test into a commercial product.
A fellow of the American Association for the Advancement of Science, Dr. Condeelis is the recipient of the Allen Foundation Scholar Award and the Hirschl Career Scientist Award. He has served on numerous study sections of the National Institutes of Health and the American Cancer Society, as a consultant to the National Cancer Institute, and on the editorial boards of several prominent journals, including theJournal of Cell Biology.

Research Profile

https://einsteinmed.edu/faculty/6712/John-Condeelis

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/9bd9420d-d79f-44fc-8f92-bbc05e519…

Lab Website Link

https://einsteinmed.edu/labs/john-condeelis/

Selected Publications

Selected Publications 2020-2022 (<a title="View complete list of publications" href="/labs/john-condeelis/publications/">See complete list of publications.)</a>
<ul class="no-bullet">
<li>Karagiannis GS, Eddy RJ, Sparano JA, Anampa Mesias J, Rohan TE, Branch CA, Condeelis JS, Entenberg D, Oktay MH. Detection of TMEM Doorways and Their Activity Required for Metastasis. Emerging Technologies for Cancer Detection and DiagnosisIn Submission.</li>
<li>Sanchez LR, Duran CL, Burt J, Lin Y, Eddy R, Harney AS, Entenberg D, Condeelis JS, Oktay MH, Karagiannis GS. The Cxcl12/Cxcr4 Signaling Pathway Biases Breast Cancer Cell Directional Migration toward TMEM Intravasation Doorways. Journal of Leukocyte Biology. In Revision.</li>
<li>Duran C, Surve CR, Ye X, Chen X, Lin Y, Harney AS, Wang Y, Kim G, Sharma VP, Entenberg D, Stanley R, Oktay MH, Condeelis JS. Revealing the signaling events at TMEM doorways provides potential targets for inhibiting breast cancer dissemination. Science Signaling. In Revision.</li>
<li>Lucotti S, Ogitani Y, Kenific C, Geri J, Kim Y, Gu J, Balaji U, Bojmar L, Shaashua Berger L, Song Y, Cioffi M, Lauritzen P, Joseph O, Asao T, Grandgenett P, Hollingsworth M, Peralta C, Pagano A, Molina H, Lengel H, Gilbert Dunne E, Jing X, Schmitter M, Zhang H, Romin Y, Manova K, Paul D, O’Reilly E, Jarnagin W, Kelsen D, Jones D, Condeelis J, Pascual V, Matei I, Bussel J, Coller B, Entenberg D, Bromberg J, Simeone D, Lyden D. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell. In Review.</li>
<li>Genna A, Alte J, Poletti M, Meirson T, Sneh T, Gendler M, Saleev N, Karagiannis G, Wang Y, Cox D, Entenberg D, Oktay M, Korcsmaros T, Condeelis J, Gil-Henn H. FAK family proteins regulate in vivo breast cancer metastasis via distinct mechanisms. Nature Communications. In Review.</li>
<li>Dalton K, Howley R, Condeelis J, Entenberg D, Borriello L. Visualization of disseminated tumor cells and metastatic outgrowth in the lung at single cell resolution via intravital imaging. In: Gligorijevic B, editor. Intravitial Microscopy: Methods and Protocols Springer; In Review.</li>
<li>Barth ND, Oktay MH, Condeelis JS, Brunton VG, Entenberg D. Ex Vivo Models to Study the Interaction of Immune Cells and Cancer Cells under Therapy. In: Gligorijevic B, editor. Intravitial Microscopy: Methods and Protocols Springer; In Review.</li>
<li>Ye X, Head T, Duran C, Jafari R, Condeelis JS, Oktay MH, Cady N, Entenberg D. Microfluidic imaging windows for direct localized engineering of the in vivo tumor microenvironment In Progress.</li>
<li>Karagiannis GS, Rivera-Sanchez L, Wang Y, Sharma VP, Entenberg D, Oktay MH, Condeelis JS. Mechanisms of MenaINV induction and host response to chemotherapy.In Progress.</li>
<li>Ye X, Jafari R, Duran C, Du W, Lin Y, Surve C, Wang Y, Hoffmann E, Inman D, Ponik S, Oktay M, Condeelis JS, Entenberg D. Intravital Imaging Tissue AlignmentIn Preparation.</li>
<li>Miller A, Parmar P, Duran C, Porcelli S, Zhang J, Condeelis JS, Entenberg D, Oktay MH. The effect of macrophage cancer cell contact and anti-estrogen therapy on induction of stem cell program using SORE6 biosensor in estrogen receptor positive breast cancer cells.In Preparation.</li>
<li>Miller A, Karadal-Ferrena B, Parmar P, Huang C, Lin Y, Ye X, Chen X, Zintiridou A, Shukla S, Eddy R, Condeelis JS, Anampa JM, Entenberg D, Xue X, Rohan TE, Oktay MH. The clinical utility of TMEM doorway score in predicting response to treatment in breast cancer patients with estrogen receptor positive and triple negative breast cancer.In Preparation.</li>
<li>Karadal-Ferrena B, Miller A, Adler E, Ginter PS, D'Alfonso T, Lin Y, Ye X, Chen X, Zintiridou A, Shukla S, Eddy R, Condeelis JS, Anampa JM, Sparano JA, Entenberg D, Xue X, Rohan TE, Oktay MH. A multi-institutional study of TMEM doorway score as prognostic biomarker in a multiracial cohort of breast cancer patients.In Preparation.</li>
<li>Karadal-Ferrena B, DeLuca M, Duran C, Barth N, Jung Y, Eddy R, Lin Y, Chen X, Zintiridou A, Ye X, Karagiannis GS, Condeelis JS, Entenberg D, Oktay MH. TMEM doorway activity and macrophage profile in lung metastasis from breast cancer.In Preparation.</li>
<li>Entenberg D, Kodandaramaiah SB, Ponik SM, Elicieri K. Design considerations for optical intravital imaging windows. J Biomed Opt. In Preparation.</li>
<li>Anampa JM, Flynn DL, Oh S, Sadan S, Xue X, Oktay MH, Condeelis JS, Sparano JA. Phase Ib clinical and pharmacodynamic study of the Tie2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.In Preparation.</li>
<li>Yang Y, Wang X, Zhang J. Pirfenidone and nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2. J Thorac Dis. 2024;16(2):1128-40. Epub 20240226. doi: 10.21037/jtd-23-1057. PubMed PMID: 38505034; PMCID: PMC10944717.</li>
<li>Oh SS, Narver HL. Mouse and Rat Anesthesia and Analgesia. Curr Protoc. 2024;4(2):e995. doi: 10.1002/cpz1.995. PubMed PMID: 38406895; PMCID: PMC10914332.</li>
<li>Migulina N, de Hilster RHJ, Bartel S, Vedder RHJ, van den Berge M, Nagelkerke A, Timens W, Harmsen MC, Hylkema MN, Brandsma CA, Burgess JK. 3-D culture of human lung fibroblasts decreases proliferative and increases extracellular matrix remodeling genes. Am J Physiol Cell Physiol. 2024;326(1):C177-C93. Epub 20231113. doi: 10.1152/ajpcell.00374.2023. PubMed PMID: 37955339.</li>
<li>Chioccioli M, Liu S, Magruder S, Tata A, Borriello L, McDonough JE, Konkimalla A, Kim SH, Nouws J, Gonzalez DG, Traub B, Ye X, Yang T, Entenberg DR, Krishnaswamy S, Hendry CE, Kaminski N, Tata PR, Sauler M. Stem cell migration drives lung repair in living mice. Dev Cell. 2024. Epub 20240214. doi: 10.1016/j.devcel.2024.02.003. PubMed PMID: 38377991.</li>
<li>Barth ND, Oktay MH, Condeelis JS, Brunton VG, Entenberg D. Ex Vivo Models to Study the Interaction of Immune Cells and Cancer Cells under Therapy. Nature Protocols Exchange. 2024. doi: <a title="Read article" href="https://doi.org/10.21203/rs.3.pex-2544/v1" target="_blank" rel="noopener">https://doi.org/10.21203/rs.3.pex-2544/v1</a>.</li>
<li>Barron SL, Wyatt O, O'Connor A, Mansfield D, Suzanne Cohen E, Witkos TM, Strickson S, Owens RM. Modelling bronchial epithelial-fibroblast cross-talk in idiopathic pulmonary fibrosis (IPF) using a human-derived in vitro air liquid interface (ALI) culture. Sci Rep. 2024;14(1):240. Epub 20240102. doi: 10.1038/s41598-023-50618-y. PubMed PMID: 38168149; PMCID: PMC10761879.</li>
</ul>

Is Open Scheduling

Off

Julio A. Aguirre-Ghiso

Read more about Julio A. Aguirre-Ghiso

Julio A. Aguirre-Ghiso

https://assets.montefioreeinstein.org/profiles/images/Aguirre-Ghiso_Julio_PhD_2x.jpg

Faculty

Expert

First Name

Julio

Last Name

Aguirre-Ghiso

Faculty ID

16974

Patient Type

Adult

Department

einstein-dept-cell-biology

einstein-dept-oncology

einstein-dept-medicine

julio.aguirre-ghiso@einsteinmed.edu

Phone

718-678-1246

Titles

Type

Academic

Department

Department of Cell Biology

Department Link

Rank

Professor

Type

Academic

Department

Department of Oncology

Rank

Professor

Division

Medical Oncology

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Oncology & Hematology

Type

Administrative

Title

Rose C. Falkenstein Chair in Cancer Research

Type

Administrative

Title

Co-Leader, Montefiore Einstein Comprehensive Cancer Center, Tumor Microenvironment & Metastasis Program

Tags

me-patientcare-cancer-research-tumor-microenvironment-metastatis

Type

Administrative

Type

Administrative

Title

Director, Cancer Dormancy Institute

Tags

me-patientcare-cancer-research-cdicore

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.845838 40.8516937)

Room

220

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Michael F. Price Center

Address Line 3

1301 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

The major challenge faced by physicians is the prevention and treatment of metastasis, the main reason for cancer mortality. Surprisingly, cancer patients presumed cured after primary tumor removal and therapy, can carry non-proliferating ‘dormant’ disseminated cancer cells (DCCs) for years before reactivating to form incurable metastasis. I focused on understanding the biology of dormant DCCs and their reactivation, to target them and prevent relapse. My team led a paradigm shift that is revealing novel cancer biology that diverges from the notion that cancer is perpetually proliferating.
 
We discovered that a reciprocal crosstalk between DCCs and the microenvironment regulates the inter-conversion between dormancy and proliferation. My lab discovered that an imbalance in p38a/b and ERK1/2 signaling regulates lineage commitment transcription factors (TF) and an epigenetic network that determines dormancy induction (Aguirre-Ghiso et al., JCB 1999, Mol Biol Cell 2001, Oncogene 2002, Liu, Aguirre-Ghiso et al., Cancer Cell, 2002, Aguirre-Ghiso et al., Cancer Res 2004, among others). This work led to identify retinoic acid and TGFb2 in the microenvironment as inducers of the high p38/ERK-signaling ratio, leading to the finding that dormancy  (quiescence) is controlled by mechanisms of adult stem cell quiescence (Adam et al., Cancer Res 2009; Bragado et al., Nat Cell Bio, 2013, Sosa et al., Nat Commun 2015; Fluegen et al., & Nat Cell Bio, 2017; Nobre et al., Nature Cancer 2021). These findings have been expanded to reveal that mesenchymal stem cell niches that control hematopoietic stem cell dormancy control dormancy of breast cancer DCCs through a TGFB2 and BMP7-dependent mechanism (Nobre et al.,Nat Cancer, 2021). My lab was one of the first to show that tumor-initiating properties and DCC dormancy are dynamically linked by epigenetic states and a transcriptional program that affects the histone code (Sosa et al., Nat Commun 2015). This work led to an epigenetic strategy to induce dormancy, which is now a clinical trial funded by the V-Foundation and TCI (NCT03572387). We also identified a “dormancy signature” and specific markers enriched in dormant prostate and breast cancer DCCs as well as in the bone marrow of breast cancer patients that predict for prolonged metastasis-free periods (Borgen et al., Breast Cancer Res 2018; Nobre et al., Nature Cancer 2021). We also found how the hypoxic microenvironment in primary tumors primes DCCs epigenetically to become dormant and evade chemotherapy (Fluegen et al., Nat Cell Bio, 2017).
 
My lab’s work has propelled new questions to the forefront of cancer research, with the unexpected discovery of the mechanisms that allow dormant breast cancer DCCs and metastasis to be initiated very early during cancer evolution disseminating during pre-malignant stages (Harper and Sosa et al., Nature, 2016 and Hosseini et al., Nature, 2016). We further discovered that innate immune cells are key to launch the early dissemination process and the success on metastatic colonization (Linde et al., Nature Commun. 2018). Our program’s impact is further highlighted by the development of successful collaborations with industry that identified pathways (Ranganathan et al., Cancer Ress 2006; 2008; Schewe and Aguirre-Ghiso, PNAS 2008; Cancer Res 2009) and drugs to kill dormant DCCs or induce dormancy of DCCs that are now part of a patent (WO201919111) and developed by a new startup company (HiberCell)(<a style="color: #903638;" href="http://www.hibercell.com/">www.hibercell.com</a>), which is conducting clinical trials developed from our findings (NCT04834778, NCT04995094),identification of potential biomarkers and the development of the first clinical trials to induce dormancy of metastatic disease in prostate cancer (NCT03572387).

Research Areas

Metastasis biology
Cancer cell dormancy
Signal transduction
Extracellular matrix
Innate immune cell function
tumor and normal organ microenvironment

Specialties

Cancer

Basic Science

Expert Tags

Tumor Microenvironment

Metastasis

Dormancy

Areas of Expertise

Tumor microenvironment

Expert Summary

Julio Aguirre-Ghiso, Ph.D., is an international leader in cancer cell dormancy and metastasis. He has helped lead a major shift in the cancer biology field by investigating how cancer cells hibernate, undetected, for long periods of time and what causes them to suddenly awaken to seed deadly, treatment-resistant metastases.
Dr. Aguirre-Ghiso’s work is revealing ways to maintain residual cancer-cell dormancy, kill dormant cancer cells, and identify biomarkers for cancer recurrence. He has founded a start-up company, HiberCell, which is developing treatments to prevent relapse. 
Dr. Aguirre-Ghiso is founding director of the <a href="https://montefioreeinstein.org/cancer/research/cdtmi">Cancer Dormancy and Tumor Microenvironment Institute</a> at the Montefiore Einstein Cancer Center. The goal of the institute is to integrate research from a range of specialties—including the biology of aging, stem cells, epigenetics, and systems biology—to address how residual cancer cells, aging, lifestyle, genetics, and treatments influence relapse across all cancers.
Dr. Aguirre-Ghiso is a reviewer for top-tier scientific journals and for federal, private, and international agencies.  His work has been published in Nature, Nature Cell Biology, Nature Cancer, Science, and Cancer Cell. He is also president of the Metastasis Research Society and has served at several leadership levels at American Association for Cancer Research.

Research Profile

https://einsteinmed.edu/faculty/16974/Julio-Aguirre-Ghiso

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/111272a9-13f2-4f87-ae26-6869ef0cd…

Lab Website Link

https://einsteinmed.edu/labs/julio-aguirre-ghiso/

Selected Publications

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"><span style="font-size: 16pt; font-variant-ligatures: normal; font-variant-numeric: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; font-variant-east-asian: normal; color: #3c7483;">Pre-Prints Available Online
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
1.     Deepak K. Singh, Eduardo Farias, Saul Carcamo, Dan Hasson, Dan Sun, Julie Cheung, Ana Rita Nobre, Nupura Kale, Maria Soledad Sosa, Emily Bernstein, Julio A. Aguirre-Ghiso. Epigenetic reprogramming of DCCs into dormancy suppresses metastasis via restored TGFβ–SMAD4 signaling bioRxiv 2021.08.01.454684; doi: <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.1101/2021.08.01.454684">https://doi.org/10.1101/2021.08.01.454684</a>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
2.     Aguirre-Ghiso JA, Nobre AR, Dalla E, et al. A Mesenchymal-like Program of Dormancy controlled by ZFP281 Serves as a Barrier to Metastatic Progression of Early Disseminated Cancer Cells. 18 January 2021, PREPRINT (Version 1) available at Research Square. <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.21203/rs.3.rs-145308/v1">https://doi.org/10.21203/rs.3.rs-145308/v1</a>
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
3.     Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Rodriguez Martinez A, Miles B, Farias E, Mezei M, Cheung JF, Nobre AR, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. A specific agonist of the orphan nuclear receptor NR2F1 suppresses metastasis through the induction of cancer cell dormancy. bioRxiv(2021).01.30.428967; doi: <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.1101/2021.01.30.428967">https://doi.org/10.1101/2021.01.30.428967</a>
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
4.     Borriello L, Coste A, Sharma VP, Karagiannis GS, Lin Y, Wang Y, Ye X, Duran C, Chen X, Dalla E, Singh DK, Oktay MH, Aguirre-Ghiso JA, Condeelis J, Entenberg D. Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. bioRxiv (2021).02.04.429798; doi: <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.1101/2021.02.04.429798">https://doi.org/10.1101/2021.02.04.429798</a>
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
5.     Mitchell Fane, Stephen Douglass, Gretchen Alicea, Marie Webster, Vito Rebecca, Gloria Marino, Yash Chhabra, Filipe Almeida, Brett Ecker, Thomas Beer, Hsin-Yao Tang, Andrew Kossenkov, David Speicher, Julio Aguirre-Ghiso, Ashani Weeraratna,  Stromal Changes In The Aged Lung Induce An Emergence From Melanoma Dormancy, 16 September (2020), PREPRINT (Version 1) available at Research Square <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.21203/rs.3.rs-61165/v1">https://doi.org/10.21203/rs.3.rs-61165/v1</a>
<p class="MsoListParagraphCxSpLast" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"><span style="font-size: 16pt; font-variant-ligatures: normal; font-variant-numeric: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; font-variant-east-asian: normal; color: #3c7483;">Peer Reviewed Original Research Contributions 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-align: justify; line-height: 24px;"> 
1.     Di Martino J, Nobre AR, Mondal C, Taha I, Farias EF, Fertig E, Naba A, Aguirre-Ghiso JA, Bravo-Cordero JJ. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy, 22 June 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-580847/v1]. Nature Cancer (2021) (Accepted for Publication)
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
2.     Casanova-Acebes M, Dalla E, Leader A, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang M, Troncoso L, Chen ST, Sastre-Perona A, Park MD, Tabachnikov A, Dhainaut M, Hamon P, Maier B, Sawai CM, Agulló-Pascual E, Schober M, Brown B, Reizis B, Marron T, Kenigsberg E, Moussion C, Benaroch P, Aguirre-Ghiso JA, Merad M. Lineage tracing reveals the unique pro-tumorigenic niche role of tissue-resident macrophages in early cancer lesions. Nature 595, 578–584 (2021). In the top 5% of all research outputs scored by Altmetric
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
3.     Nobre R, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J, Johnson J, Russnes HG, Bravo-Cordero JJ, Birbrair A, Naume B, Azhar M, Frenette PS, Aguirre-Ghiso JA. Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2. Nature Cancer 2, 327–339 (2021). <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.1038/s43018-021-00179-8">https://doi.org/10.1038/s43018-021-00179-8</a> In the top 5% of all research outputs scored by Altmetric
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
4.     Lam T, Aguirre-Ghiso JA, Geller MA, Aksan A, Azarin SM. Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy. Biotechnol Bioeng. (2020) Oct;117(10):3066-3080. doi: 10.1002/bit.27479. Epub 2020 Jul 9.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
5.     Teh JL, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso JA, Aplin AE. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. Mol Cancer Ther. (2020) May 19: molcanther.1016.2019. doi: 10.1158/1535-7163.MCT-19-1016. Epub ahead of print. PMID: 32430489.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
6.     Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S. An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nat Cell Biol. (2019) Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
7.     Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner PB, Aplin AE, Aguirre-Ghiso JA, Benovic JL. Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. (2019) Apr;17(4):963-973. doi: 10.1158/1541-7786.MCR-18-0574. Epub 2018 Dec 19. In the top 5% of all research outputs scored by Altmetric and picked up by 16 news stories from 15 outlets.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
8.     Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Research(2018) 20 (1), 120. In the top 5% of all research outputs scored by Altmetric and picked up by 9 news stories from 9 outlets.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; vertical-align: baseline;"> 
9.     Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias EF, Harper K, Tardio E, Reyes Torres I, Jones J, Condeelis J, Merad M, and Aguirre-Ghiso JA. Macrophages orchestrate breast cancer early dissemination and metastasis. Nature Communications 9, 21(2018) doi:10.1038/s41467-017-02481-5. In the top 5% of all research outputs scored by Altmetric. Highlighted in Faculty of 1000 Prime: El-Deiry W and Zhao S: F1000Prime Recommendation of [Linde N et al., Nat Commun 2018 9(1):21]. In F1000Prime, 11 Jan 2018; 10.3410/f.732394311.793541160. Highlighted in Science Translational Medicine:
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: 22.5pt; vertical-align: baseline;"><a style="color: #903638; text-decoration: underline;" href="https://stm.sciencemag.org/content/10/425/eaar7521?intcmp=trendmd-stm">… style="background-color: white;">https://stm.sciencemag.org/content/10/425/eaar7521?intcmp=trendmd-stm</…;
<p class="MsoListParagraphCxSpFirst" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraphCxSpLast" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l9 level1 lfo8; tab-stops: 535.5pt; mso-layout-grid-align: none; text-autospace: none;">10.  Entenberg D, Pastoriza JM, Oktay MH, Voiculescu S, Wang Y, Sosa MS, Aguirre-Ghiso JA, Condeelis J. Time-lapsed, large-volume, high-resolution intravital imaging for tissue-wide analysis of single cell dynamics. Methods(2017) Sep 1; 128:65-77. doi: 10.1016/j.ymeth.2017.07.019.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraph" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l9 level1 lfo8; tab-stops: 535.5pt; mso-layout-grid-align: none; text-autospace: none;">11.  Fluegen G, Avivar-Valderas A, WangY, PadgenM, WilliamsJK, Verkhusha V, Cheung JF, Entenberg D, Castracane J, Keely PJ, Condeelis J, Aguirre-Ghiso JA.  Phenotypic heterogeneity of disseminated tumor cells is predetermined by primary tumor hypoxic microenvironments. Nature Cell Biology (2017) doi:10.1038/ncb3465.Cover Article. Highlighted in Science Translational Medicine Editor’s Choice, Science Translational Medicine 15 Feb 2017: Vol. 9, Issue 377, eaam6063 DOI: 10.1126/scitranslmed.aam6063
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraphCxSpFirst" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l9 level1 lfo8; mso-layout-grid-align: none; text-autospace: none;">12.  Harper K, Sosa MS, Hosseini H, Entenberg D, Avivar-Valderas A, Nagi C, Davis RJ, Farias EF, Condeelis J, Klein C, Aguirre-Ghiso JA. Mechanism of early dissemination and metastasis during early stages of HER2+ mammary cancer. Nature (2016) Dec 14. doi: 10.1038/nature20785. [Epub ahead of print] PMID:27974799. Paper highlighted in Nature News and Views. Nature. 2016 Dec 14. doi: 10.1038/nature21104. Highlighted by Faculty of 1000. <a style="color: #903638; text-decoration: underline;" href="https://f1000.com/prime/727099751">https://f1000.com/prime/727099751</a><… style="font-size: 12pt; color: #ff6600;">; Highlighted in Nature Reviews  Cancer <a style="color: #903638; text-decoration: underline;" href="http://www.nature.com/nrc/journal/v17/n2/full/nrc.2017.4.html">… style="font-size: 12pt;">http://www.nature.com/nrc/journal/v17/n2/full/nrc.2017.4.html</e…;
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraphCxSpLast" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l9 level1 lfo8; mso-layout-grid-align: none; text-autospace: none;">13.  Hosseini, H, Harper K, Obradovic M, Sosa MS, Nanduri LK, Werno C, Hoffman, M, Ehrl C, Maneck M, Patwary N, Haunschild G, Reimelt C, Weeber F, Hartkopf A, Taran FA, Brucker SY, Fehm T, Meister G, Aguirre-Ghiso JA, Klein CA. Early dissemination seeds metastasis in breast cancer. Nature. (2016) Dec 14. doi: 10.1038/nature20609. [Epub ahead of print] PMID:27974798. Paper highlighted in Nature News and Views. Nature. 2016 Dec 14. doi: 10.1038/nature21104. Highlighted in Nature Reviews Cancer <a style="color: #903638; text-decoration: underline;" href="http://www.nature.com/nrc/journal/v17/n2/full/nrc.2017.4.html">… style="font-size: 12pt;">http://www.nature.com/nrc/journal/v17/n2/full/nrc.2017.4.html</e…;
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
14.  Yumoto K, Eber MR, Wang J, Cackowski FC, Decker AM, Lee E, Nobre AR, Aguirre-Ghiso JA, Jung Y, Taichman RS. Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Scientific Reports (2016) Nov 7; 6:36520. doi: 10.1038/srep36520.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
15.  Morris BA, Burkel B, Ponik SM, Fan J, Condeelis JS, Aguire-Ghiso JA, Castracane J, Denu JM, Keely PJ. Collagen Matrix Density Drives the Metabolic Shift in Breast Cancer Cells. EBioMedicine (2016) Nov; 13:146-156. doi: 10.1016/j.ebiom.2016.10.012. PubMed PMID: 27743905.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
16.  Cackowski FC, Eber MR, Rhee J, Decker A, Yumoto K, Berry JE, Lee E, Shiozawa Y, Jung Y, Aguirre-Ghiso JA,Taichman RS. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy. J Cell Biochem(2016) Oct 18. doi: 10.1002/jcb.25768. PMID: 27753136
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
17.  Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF, Brown BD, Gaspar-Maia A, Bernstein E. Cbx8 acts non-canonically in breast cancer to promote Notch signaling. Cell Reports (2016) Jul 12;16(2):472-86. doi: 10.1016/j.celrep.2016.06.002. Epub 2016 Jun 23. PMID: 27346354
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
18.  Williams JK, Entenberg D, Wang Y, Avivar-Valderas A, Padgen M, Clark A, Aguirre-Ghiso JA, Castracane J, Condeelis JS. Validation of a device for the active manipulation of the tumor microenvironment during intravital imaging. Intravital. (2016)
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
19.  Szulczewski JM, Inman DR, Entenberg D, Aguirre-Ghiso JA, Castracane J, Condeelis J, Eliceiri KW, Keely PJ. In Vivo Visualization of Stromal Macrophages via label-free FLIM-based metabolite imaging. Scientific Reports(2016) May 25; 6:25086. doi: 10.1038/srep25086. PMID: 27220760
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
20.  Li M, Pathak RR, Lopez-Rivera E, Friedman SL, Aguirre-Ghiso JA, Sikora AG. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. J Vis Exp. (2015) Oct 9; (104). doi: 10.3791/52411.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
21.  Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso JA, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe DM. Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo. Leukemia. (2015) Jun 24. doi: 10.1038/leu.2015.153. [Epub ahead of print] PMID: 26104660
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
<p class="MsoListParagraphCxSpFirst" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-GhisoJA. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer (2015) May 30; 15:444. doi: 10.1186/s12885-015-1460-1. PMCID: PMC4448210. Highlighted by BMC Cancer in the “Highly Accessed” category.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
22.  Hasegawa D, Calvo V, Avivar-Valderas A, Lade A, Chou HI, Lee YA, Farias EF, Aguirre-Ghiso JA, Friedman SL. Epithelial Xbp1 is Required for Cellular Proliferation and Differentiation During Mammary Gland Development. Mol Cell Biol. (2015) Feb 23. pii: MCB.00136-15. PMID: 25713103. Cover article for the Feb 23 issue of Mol Cell Biol.
<p class="MsoListParagraphCxSpLast" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
23.  Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, Ekpin E, George A, Zheng Y, Lam HM, Morrissey C, Chung CY, Farias EF, Bernstein E, Aguirre-Ghiso JA. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nat Commun (2015) Jan 30; 6:6170. doi: 10.1038/ncomms7170. PubMed PMID:25636082; PubMed Central PMCID: PMC4313575. In the top 10% of all articles ever tracked by Altmetric.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
24.  Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Characterization of single disseminated prostate cancer cells Reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget (2014) Oct 30;5(20):9939-51. PubMed PMID: 25301725; PubMed Central PMCID: PMC4259449.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
25.  Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso JA, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.Cancer Res. (2014) Feb 15;74(4):1067-78. doi: 10.1158/0008-5472.CAN-13-0588. Epub 2014 Jan 7. PMID: 24398473 [PubMed - indexed for MEDLINE]
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
26.  Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM, Aguirre-Ghiso JA. TGFβ2 dictates disseminated tumour cell fate in target organs through TGFβ-RIII and p38α/β signalling. Nat. Cell. Bio. (2013).Nov;15(11):1351-61. doi: 10.1038/ncb2861. Epub 2013 Oct 27. PMID: 24161934;PMCID: not available. Featured in Nat Cell Bio Cover same issue. Highlighted in Science Signaling Editor’s Choice, Cancer Research Breaking Advances section and several public news outlets. Featured in the Cover of the November 15th issue of Nat Cell Bio. Ranks #6 for articles of similar age in Nat Rev Cancer and is in the top 5% of all articles ever tracked by Altmetric. 
<p class="MsoListParagraphCxSpLast" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
27.  Begley U, Sosa MS, Avivar-Valderas A, Patil A, Endres L, Estrada Y, Chan CTY, Su D, Dedon PC, Aguirre-Ghiso JA, Begley T. A human tRNAmethyltransferase 9-like protein prevents tumor growth by regulating LIN9 and the hypoxic response. EMBO Mol Med (2013) Feb 4. doi: 10.1002/emmm.201201161.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
28.  Avivar-Valderas A, Bobrovnikova-Marjon E, Diehl JA, Bardeesy N, Debnath J, Aguirre-Ghiso JA. Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK.  Oncogene(2012), Nov 19. doi: 10.1038/onc.2012.512. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
29.  Kim RS, Avivar-Valderas A, Estrada A, Bragado P, Sosa MS, Aguirre-Ghiso JA, Segall JE. Dormancy signatures and metastasis in estrogen receptor positive breast cancer. PLoS One (2012); 7(4):e35569. Epub 2012 Apr 18.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
30.  Bragado P, Estrada Y, Sosa MS, Avivar-Valderas A, Cannan D, Genden E, Teng M, Ranganathan AC, Wen HC, Kapoor A, Bernstein E, Aguirre-Ghiso JA. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS One. (2012); 7(1):e29974. PMCID: PMC3262798. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
31.  Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso JA, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. (2012) May; 27(5):1580-6. doi: 10.3892/or.2012.1679.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
32.  Gutiérrez-Uzquiza Á, Arechederra M, Bragado P, Aguirre-Ghiso JA, Porras A. p38a mediates cell survival in response to oxidative stress via induction of antioxidant genes. Effect on p70S6K pathway. J Biol Chem. (2012)Jan 20;287(4):2632-42. Epub 2011 Dec 2.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
33.  Fu S, Rivera M, Ko EC, Sikora AG, Chen CT, Vu HL, Cannan D, Eisenstein S, Rosenstein BS, Aguirre-Ghiso JA, Chen SH, Kao J. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. J Cell SciTher (2011) S1:002. doi:10.4172/2157-7013.S1-002.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
34.  Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, Diehl JS, Nagi C, Debnath J, Aguirre-Ghiso JA, PERK integrates autophagy and oxidative stress  responses to promote survival during ECM detachment. Mol Cell Biol. (2011) Sep; 31(17):3616-29. PMC3165554 (Cover article) 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
35.  Wen HC, Avivar-Valderas A, Sosa MS, Girinius N, Farias EF, Davis R, Aguirre-Ghiso JA. p38 signaling regulates ATF2/c-Jun and BimEL to induce anoikis and lumen formation during mammary morphogenesis. Science Signaling (2011) 4 (174), ra34. [DOI: 10.1126/scisignal.2001684].http://stke.sciencemag.org/cgi/content/abstract/sigtrans;4/174/ra34</sp…;
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
36.  Ishii Y, Papa Y, Bahadur U, Yue Z, Aguirre-Ghiso JA, Shioda T, Waxman S, Germain D. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of theestrogen receptor, which leads to a pro-apoptotic unfolded protein response. Clin. Cancer Res. (2011) Feb 3. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
37.  Sequeira SJ, Wen HC, Avivar-Valderas A, Aguirre-Ghiso JA. Inhibition of eIF2a dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.BMC Cell Biology. (2009) Sep 15;10:64. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
38.  Schewe DM. Aguirre-Ghiso JA. Inhibition of eIF2 dephosphorylation eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. (2009) Feb 15;69(4):1545-52.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
39.  Adam AP, George A, Bragado P, Iglesias BV, Schewe D, Ranganathan A, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Computational identification of a p38SAPK regulated transcription factor network required for tumor cell quiescence. Cancer Res. (2009) Jul 15; 69(14):5664-72. Epub 2009 Jul 7.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
40.  Schewe DM, Aguirre-Ghiso JA. ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci USA (2008) Jul 29;105(30):10519-24. Highlighted in “This week in PNAS” section of the journal. <a style="color: #903638; text-decoration: underline;" href="http://www.pnas.org/content/105/30/10271.full?sid=79541a8a-11a2-41cc-ae… style="color: #ff6600;"> Faculty of 1000 evaluation: <a style="color: #903638; text-decoration: underline;" href="http://www.f1000biology.com/article/id/1119501/evaluation">…;
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
41.  Ranganathan AC, Ohja S, Kourtidis A, Conklin D, Aguirre-Ghiso JA. Dual function of PERK in tumor cell growth arrest and survival. Cancer Res (2008); 68(9): 1–9.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
42.  Sequeira SJ, Ranganathan AC, Adam AP, Iglesias BV, Farias EF, Aguirre-Ghiso JA. Inhibition of Proliferation by PERK Regulates Mammary Acinar Morphogenesis and Tumor Formation. PLoS ONE. (2007) Jul 18; 2:e615.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
43.  Baron TE, Lastro MT, Ranganathan AC, Tenenbaum SA, Conklin DS, Aguirre-Ghiso JA. Ribonomic and Short Hairpin RNA Gene Silencing Methods to Explore Functional Gene Programs Associated with Tumor Growth Arrest. Methods Mol Biol. (2007); 383:227-44. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
44.  Shinohara M, Mikhailov AV, Aguirre-Ghiso JA, Rieder CL. ERK1/2 activation is required for timely progress through early G2 but it is not directly involved in the G2/M or M/A transitions in mammalian cells. Molecular Biology of the Cell. (2006) Dec 1st.17: 5227-5240.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
45.  Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski LA. Region in uPAR domain III controlling a functional association with a5b1 integrin and tumor growth. J. Biol. Chem. (2006) May 26; 281(21): 14852-63.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
46.  Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. <a name="OLE_LINK9"></a>Functional coupling of p38-induced upregulation of BiP and activation of RNA-dependent protein kinase–like ER kinase (PERK) to drug resistance of dormant carcinoma cells. Cancer Research (2006); 66: (3) 1702-11.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
47.  Connor KM, Subbaram S, Regan KJ, Nelson KK, Mazurkiewicz JE, Bartholomew PJ, Aplin AE, Tai YT, Aguirre-Ghiso JA, Flores  SC, Melendez JA. Mitochondrial H2O2 Regulates the Angiogenic Phenotype Via PTEN Oxidation.  J. Biol. Chem. (2005) 29; 280(17): 16916-24.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
<p class="MsoNormal" style="text-indent: -.25in; mso-pagination: none; mso-list: l9 level1 lfo8; tab-stops: 56.0pt 84.0pt 112.0pt 140.0pt 168.0pt 196.0pt 224.0pt 3.5in 280.0pt 308.0pt 336.0pt; mso-layout-grid-align: none; text-autospace: none; margin: 0in 9.0pt .0001pt 22.5pt;">48.  Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. GFP tagging of ERK and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res (2004); 64(20): 7336-45.Faculty of 1000 evaluation at: <a style="color: #903638; text-decoration: underline;" href="http://www.f1000biology.com/article/15492254/evaluation">ww…;
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
49.  Mazzoni E, Adam A, Bal de Kier Joffe E, Aguirre-Ghiso JA. Immortalized mammary epithelial cells overexpressing PKC acquire a malignant phenotype and become tumorigenic in vivo. Molecular Cancer Res. (2003) 1:776-787
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
50.  Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res. (2003); 63(7): 1684-95.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
51.  Puricelli L, Proiettii CJ, Labriola L, Salatino M, Balana ME, Aguirre-Ghiso JA, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffe E, Elizalde PV. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int. J. Cancer. (2002) 100(6): 642-53.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
52.  Liu D, Aguirre-Ghiso JA, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell (2002); 1: 445-457(Cover). Preview in the same issue: <a style="color: #903638; text-decoration: underline;" href="http://www.cell.com/cancer-cell/abstract/S1535-6108(02)00076-4"><strong… style="text-transform: uppercase;"> Faculty of 1000 Evaluation at: <a style="color: #903638; text-decoration: underline;" href="http://www.f1000biology.com/article/12124174/evaluation">ww…;
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
53.  Aguirre-Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces human carcinoma dormancy in vivo. Oncogene (2002) 21(16): 2513-24.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
54.  Ladeda V, Frankel P, Feig LA, Foster DA, Bal de Kier Joffe E, Aguirre-Ghiso JA. RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts. BiochemBiophys Res Commun. (2001) 283(4): 854-61.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
55.  Aguirre-Ghiso JA, Liu D, Mignatti D, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell (2001). 12, 4, 863-879. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
56.  Aguirre-Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy due to urokinase receptor down-regulation in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. (1999) 147, 89-103. Highlighted in the In Brief section of JCB.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
57.  Aguirre-Ghiso JA, Frankel P, Farías E, Lu Z, Jiang H, Olsen A, Feig L, Bal de Kier Joffé E, Foster D. Ral-A requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator. Involvement of metalloproteinases. Oncogene (1999), 18, 4718-4725.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
58.  Urtreger AJ, Aguirre-Ghiso JA, Werbahj S, Puricelli L, Muro A, Bal de Kier Joffé E. Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells.Int. J. Cancer, (1999), vol. 82, 748-753.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
59.  Ladeda V, Aguirre-Ghiso JA, Bal de Kier Joffé E. Function and Expression of CD44 During Spreading and Migration of Murine Carcinoma cells. Exp. Cell Res. (1998); 242:515-527.
<p class="ColorfulList-Accent11" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
60.  Aguirre-Ghiso JA, Farías EF, Alonso DF, Bal de Kier Joffé E. Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine-kinase pathway in mammary tumor cells. Int. J.  Cancer (1998) 76: 362-367.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
61.  Farías EF, Aguirre-Ghiso JA, Ladeda V, Bal de Kier Joffé E. Verapamil Inhibits Proteases Production, Local Invasion and Metastasis Development of Murine Carcinoma Cells. Int. J. Cancer. (1998) 78 (6): 727-734.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
62.  Aguirre-Ghiso JA, Farías EF, Alonso DF, Arregui C, Bal de Kier Joffé E E. A Phospholipase D and Protein Kinase C Inhibitor Blocks the Spreading of Murine Mammary Adenocarcinoma Cells Altering F-Actin and Integrin Point Contact Distribution. Int. J. Cancer. (1997) 71: 881-890.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
63.  Aguirre-Ghiso JA, Alonso DF, Farías E, Bal de Kier Joffé E. Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D and protein kinase C pathways in murine mammary adenocarcinoma cells. Biochem. Biophys. Acta (1997) 1356: 171-184. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
64.  Aguirre-Ghiso JA, Diament M, D'elia I, Bal de Kier Joffé E, Klein S. Effect of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth. Tumor Biol. (1997); 18: 41-52.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
65.  Aguirre-Ghiso JA, Farías E, Fernandez DM, Alonso DF, Bal de Kier Joffé E. Down modulation of tumor cells-associated proteolytic activity by n-butanol treatment in cultured murine mammary adenocarcinoma cells. Int. J Oncol. (1996); 8: 35-39.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.25in;"> 
66.  Klein S, Jasnis MA, Diament M, Davel L, Aguirre Ghiso JA, de Bonaparte YP. Immunomodulation by soluble factors from tumor cells cultured in vivo in diffusion chambers. Tumor Biol. (1994);15: 160-165.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"><span style="font-size: 14pt; font-variant-ligatures: normal; font-variant-numeric: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; font-variant-east-asian: normal; color: #66a6b8;"> 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"><span style="font-size: 16pt; font-variant-ligatures: normal; font-variant-numeric: normal; font-variant-caps: small-caps; font-variant-alternates: normal; font-variant-position: normal; font-variant-east-asian: normal; color: #66a6b8;">Reviews, Commentaries, Perspectives and other Peer Reviewed Publications 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
1.     Aguirre-Ghiso JA. Translating the Science of Cancer Dormancy to the Clinic. Cancer Res (2021)August 24. DOI: 10.1158/0008-5472.CAN-21-1407
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
2.     Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. (2021) Jan 7:clincanres.4092.2020. doi: 10.1158/1078-0432.CCR-20-4092.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
3.     Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer (2020). <a style="color: #903638; text-decoration: underline;" href="https://doi.org/10.1038/s43018-020-0088-5">https://doi.org/10.1038/s43018-020-0088-5</a>. In the top 5% of all research outputs scored by Altmetric
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
4.     Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salomé B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, Gümüş ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM; Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. (2020) Jun 16;52(6):910-941. doi: 10.1016/j.immuni.2020.05.002. Epub 2020 May 6.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 0.5in; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
5.     Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA; Board Members of the Metastasis Research Society. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin. Exp. Metastasis. (2019) Aug;36(4):305-309. doi: 10.1007/s10585-019-09972-3. Epub 2019 May 17.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
6.     Aguirre-Ghiso JA. How dormant cancer persists and reawakens. Science. (2018) Sep 28;361(6409):1314-1315. doi: 10.1126/science.aav0191.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
7.     Aguirre-Ghiso JA, MS Sosa. Emerging topics on disseminated cancer cell dormancy and the paradigm of metastasis. Annual Review of Cancer Biology (2018), 2, 377-393
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
8.     Nobre AR, Entenberg D, Wang Y, Condeelis J, Aguirre-Ghiso JA. The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol. (2018) Jul 21. pii: S0962-8924(18)30109-0. doi: 10.1016/j.tcb.2018.06.008. [Epub ahead of print] Review. PMID: 30041830
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
9.     Fingleton B, Lange K, Caldwell B, Bankaitis KV; Board of the Metastasis Research Society. Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example. ClinExp Metastasis. (2017) Dec;34(8):443-447. doi: 10.1007/s10585-017-9872-8. Epub 2018 Feb 26 PMID: 29484519
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraphCxSpMiddle" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l17 level1 lfo7; mso-layout-grid-align: none; text-autospace: none;">10.  Linde N, Fluegen G, Aguirre-Ghiso JA. The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. (2016); 132:45-71. doi: 10.1016/bs.acr.2016.07.002. Epub 2016 Aug 25. PMID:27613129.
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoListParagraphCxSpMiddle" style="margin-left: 22.5pt; mso-add-space: auto; text-indent: -.25in; mso-pagination: none; mso-list: l17 level1 lfo7; mso-layout-grid-align: none; text-autospace: none;">11.  Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2016) Jan 2;12(1):1-222. No abstract available. PMID: 26799652
<p class="MsoListParagraphCxSpLast" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
12.  Goossens N, Hoshida Y, Aguirre-Ghiso JA. Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance. EMBO Mol Med (2015) Aug 3. pii: e201505284. doi: 10.15252/emmm.201505284. [Epub ahead of print]
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
13.  Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">dormancy: an awakening field. Nat Rev Cancer (2014) Sep;14(9):611-22. doi:
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">10.1038/nrc3793. Epub 2014 Aug 14. Review. PubMed PMID: 25118602; PubMed Central 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">PMCID: PMC4230700.
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">-Cover article for the September 14th issue of Nat Rev Cancer
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">-Ranks 6 for articles of similar age in Nat Rev Cancer and is in the top 5% of all articles ever tracked by Altmetric. 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 0.5in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
14.  Linde N, Sosa MS, Aguirre-Ghiso JA. Integration of microenvironmental and stress signaling antagonizes colorectal cancer progression. EMBO J. (2014) Aug 18;33(16):1737-9. doi: 10.15252/embj.201489364. Epub 2014 Jul 14. PubMed PMID: 25024435; PubMed Central PMCID: PMC4195757. 
<p class="MsoListParagraphCxSpMiddle" style="margin: 0in 0in 0.0001pt 22.5pt; font-size: 10pt; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
15.  Avivar-Valderas A, Wen HC, Aguirre-Ghiso JA. Stress signaling and the shaping 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">of the mammary tissue in development and cancer. Oncogene (2014) Nov
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">27;33(48):5483-90. doi: 10.1038/onc.2013.554. Epub 2014 Jan 13. Review. PubMed
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">PMID: 24413078; PubMed Central PMCID: PMC4096615. 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
16.  Aguirre-Ghiso, JA, Bragado P, Sosa MS. Metastasis awakening: targeting dormant cancer. Nat Med. (2013) Mar;19(3):276-7. doi: 10.1038/nm.3120. PMID: 23467238 [PubMed - indexed for MEDLINE] PMCID: PMC3651698 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
17.  Sosa MS, Bragado P, Debnath J, Aguirre-Ghiso JA. Regulation of tumor cell dormancy by tissue microenvironments and autophagy. AdvExp Med Biol. (2013);734:73-89. doi: 10.1007/978-1-4614-1445-2_5. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
18.  Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al., Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) Apr;8(4):445-544.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
19.  Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA. Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res. (2012); 195:25-39. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
20.  Cagan RL, Aguirre-Ghiso JA. A local view of cancer. Dev Cell. (2012) Mar 13;22(3):472-4. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
21.  Genden EM, Aguirre-Ghiso JA. Oropharyngeal cancer biology and treatment: insights from messenger RNA sequence analysis and transoral robotic surgery. Mayo Clin Proc. (2012) Mar;87(3):211-2.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
22.  Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. Molecular Pathways: ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Invited Article. Clin. Cancer Res. (2011) Sep 15;17(18):5850-7.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
23.  Prince A, Aguirre-Ghiso JA, Genden E, Posner M, Sikora A. Head and neck squamous cell carcinoma: new translational therapies. Mt. Sinai J. Med. (2010). 77 (6): 684-99. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
24.  Aguirre-Ghiso JA. On the theory of tumor self-seeding: implications for metastasis progression in humans. Breast Cancer Res. (2010) Apr 28;12(2):304. Viewpoint 
<p class="MsoNormal" style="margin: 0in 9pt 2pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
25.  Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. (2010)Feb;23(1):41-56. Epub 2009 Oct 19. 
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 27pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
26.  Allgayer H, Aguirre-Ghiso JA. The urokinase receptor (u-PAR) - a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS (2008);116 (7-8) 602-614.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
27.  Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer. (2007). Nov; 7(11): 834-46. Invited peer reviewed article (Cover and featured article).  <a style="color: #903638; text-decoration: underline;" href="http://www.nature.com/nrc/journal/v7/n11/index.html">http:/…;
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 41.05pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -35.65pt;"> 
28.  Aguirre-Ghiso JA. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle. (2006) Aug; 5(16): 1740-3. (Guest Editor). Introductory Review. Invited peer reviewed article. Cover.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
29.  Ranganathan AC, Adam AP and Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle. (2006) Aug; 5(16): 1799-807. Cover.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
30.  Ranganathan AC, Adam AP, Zhang L, and Aguirre-Ghiso JA. Tumor cell dormancy induced by p38SAPK and ER-stress signaling; an adaptive advantage for metastatic cells? Cancer Biology & Therapy (2006) Jul; 5(7): 729-35.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
31.  Tenenbaum SA, Aguirre-Ghiso JA. Dephosphorylation Shows SR Proteins the Way Out. Molecular Cell (2005); 20 (4); 499-501.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
32.  Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Current Opinion in Cell Biology (2000) 12(5): 613-20.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
33.  Bal de Kier Joffe E, Mazzoni EO, Aguirre-Ghiso JA. Signaling pathways regulating the expression of proteases during tumor progression. (In Spanish) Medicina (B Aires) (2000); 60:34-40.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
34.  Ossowski L, Aguirre-Ghiso JA, Liu D, Yu W, Kovalski K. The role of plasminogen activator receptor in cancer invasion and dormancy. Medicina (Buenos Aires) (1999) 59, 547-552.
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 45pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; text-indent: -0.5in;"> 
35.  Aguirre-Ghiso JA, Alonso DF, Farías EF, Gomez D, Bal de Kier Joffé E. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur. J. Biochem.(1999) 263, 2, 295-304 (Cover).
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;">Books and Book Chapters
<ol style="margin-bottom: 0in; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; margin-top: 0in;" start="1" type="1">
<li class="MsoNormal" style="margin-right: 9.0pt; mso-list: l16 level1 lfo2; tab-stops: list .5in;">Sosa MS, Bragado P, Debnath J, Aguirre-Ghiso JA. Regulation of Tumor Cell Dormancy by Tissue Microenvironments and Autophagy. Systems Biology of Tumor Dormancy. Editors, Enderling H, Almog N and Hlatky L. (2012) Springer Science + Business Media, INC.<a style="color: #903638; text-decoration: underline;" href="http://www.springerlink.com/content/u44l178561014r11/">http://www.sprin…;
</ol>
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<ol style="margin-bottom: 0in; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; margin-top: 0in;" start="2" type="1">
<li class="MsoNormal" style="margin-right: 9.0pt; mso-list: l16 level1 lfo2; tab-stops: list .5in;">Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA. Microenvironments dictating tumor cell dormancy. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. (Eds: K. Pantel, C. Sotiriou, M. Ignatiadis). Recent Results Cancer Res. (2012); 195:25-39. doi: 10.1007/978-3-642-28160-0_3. </li>
</ol>
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0.25in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
<ol style="margin-bottom: 0in; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; margin-top: 0in;" start="3" type="1">
<li class="MsoNormal" style="margin-right: 9.0pt; mso-pagination: none; mso-list: l16 level1 lfo2; tab-stops: list .5in; mso-layout-grid-align: none; text-autospace: none;">Aguirre-Ghiso JA, Alonso DF, Farias EF. Function and expression of the uPA/uPAR system in cancer metastasis.  Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press, Editors: Danny Welch, Danny R. Welch, Ph.D., David C. Lyden, MD, PhD, and Beth Psaila, MD. (2009).<a style="color: #903638; text-decoration: underline;" href="http://www.springer.com/biomed/cancer/book/978-1-4419-6614-8">http://ww…;
</ol>
<p class="MsoNormal" style="margin: 0in 9pt 0.0001pt 0.5in; font-size: medium; font-family: 'Times New Roman', serif; caret-color: #000000; color: #000000; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none;"> 
 
<ol style="margin-bottom: 0in; margin-top: 0in;" start="4" type="1">
<li class="MsoNormal" style="margin-right: 9.0pt; mso-list: l16 level1 lfo2; tab-stops: list .5in;">Bragado P, Ranganathan AC, Aguirre-Ghiso JA. Dormancy of Disseminated Tumor Cells: Reciprocal crosstalk with the microenvironment. The Tumor Microenvironment-Cancer Drug Discovery and Development. Springer Science + Business Media LLC, Humana Press. Dr. Rebecca Bagley, Editor. (2010), Part 2, pp229-254. <a href="http://www.cambridge.org/gb/knowledge/isbn/item5738926/?site_locale=en_…;
</ol>

Is Open Scheduling

Off

Edward Chu

Read more about Edward Chu

Edward Chu

https://assets.montefioreeinstein.org/profiles/images/16610-edward-chu.jpg

Faculty

Expert

First Name

Edward

Last Name

Chu

NPI

1164403168

Faculty ID

16610

Patient Type

Adult

Department

einstein-dept-oncology

einstein-dept-medicine

einstein-dept-molecular-pharmacology

edward.chu@einsteinmed.edu

Phone

718-430-2303

Titles

Type

Academic

Department

Department of Oncology

Rank

Professor

Division

Medical Oncology

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Oncology & Hematology

Type

Academic

Department

Department of Molecular Pharmacology

Department Link

Rank

Professor

Type

Administrative

Title

Director, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-about-directors-deputy-directors

me-patientcare-cancer-research-therapeutics

Type

Administrative

Type

Administrative

Title

The Carol and Roger Einiger Professor of Cancer Medicine

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Chanin Building

Room

209

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Specialties

Cancer

Expert Tags

Colorectal Cancer

Areas of Expertise

Colorectal cancer research & treatment

Cancer pharmacology & drug development

Chinese herbal medicine & chemotherapy side effects

Expert Summary

Dr. Chu is an NIH-funded basic, translational, and clinical investigator, and clinical oncologist, with a long history of developing and leading phase I and phase II clinical trials, particularly for colorectal cancer and other gastroenterology cancers. His research has also focused on the molecular mechanisms underlying drug resistance. Additionally, he has studied Chinese herbal medicine and its integration with standard care with the goal of improving outcomes and reducing the toxic side effects of chemotherapy.

Research Profile

https://einsteinmed.edu/faculty/16610/Edward-Chu

CHAM Provider

Off

Professional Title

M.D.

M.M.S.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/97d8f496-64c0-4fd2-a418-1853a17c1…

Is Open Scheduling

Off

Ulrich G. Steidl

Read more about Ulrich G. Steidl

Ulrich G. Steidl

https://assets.montefioreeinstein.org/profiles/images/Steidl_Ulrich_MD_PhD_2x.jpg

Faculty

Expert

First Name

Ulrich

Last Name

Steidl

Faculty ID

11118

Patient Type

Adult

Department

einstein-dept-cell-biology

einstein-dept-oncology

einstein-dept-medicine

ulrich.steidl@einsteinmed.edu

Phone

718-430-3437

Titles

Type

Academic

Department

Department of Cell Biology

Department Link

Rank

Professor

Type

Academic

Department

Department of Oncology

Rank

Professor

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Type

Administrative

Title

Chair, Department of Cell Biology

Tags

me-patientcare-cancer-research-stem-cell-cancer-biology

Type

Administrative

Title

Edward P. Evans Endowed Professor for Myelodysplastic Syndromes

Type

Administrative

Title

Co-Director, Blood Cancer Institute

Tags

me-patientcare-cancer-research-blood-cancer-institute-directors

Type

Administrative

Type

Administrative

Title

Deputy Director, and Associate Director for Basic Science, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-about-directors-deputy-directors

me-patientcare-cancer-research-cdtmi

me-patientcare-cancer-research-cdtmi-members

Type

Administrative

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Chanin Building

Room

601

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

<h6>Molecular Mechanisms and Targeting of Pre-Leukemic Stem Cells in Normal and Malignant Hematopoiesis</h6>
Hematopoiesis maintains a life-long supply of the entire spectrum of highly specialized blood cells. This process relies on a small number of pluripotent hematopoietic stem cells (HSC).
Recent experimental evidence has shown that acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS) arise from an unexepctedly diverse pool of pre-leukemic stem cells (preL-SC), preceding the formation of fully transformed leukemia stem cells (LSC). Polyclonal Pre-LSC as well as LSC are also key drivers of therapy resistance and disease progression. Defining the molecular mechanisms in pre-LSC and their progression to fully transformed LSC is critical to understanding the genesis of leukemia and to developing therapeutic strategies by which these processes can be targeted.
Recent findings from our own group and others have demonstrated a critical role of transcription dynamics and plasticity, as well as mediators of aberrant signaling in the genesis and function of HSC, pre-LSC and LSC. To identify and functionally study implicated pathways we are studying murine genetic models as well as primary human samples from patients with MDS and leukemia. Our studies aim at the development of targeted, pre-LSC- and LSC-directed therapies, which could ultimately also be employed for precision prevention of relapse/progression, or "cancer interception".

Research Areas

hematopoiesis; stem cell origin of cancer; leukemia; AML; MDS; hematopoietic stem cells (HSC); (pre)leukemic stem cells (LSC); transcription dynamics; molecular noise; epigenetics; targeted therapy; drug development; translational computational biology

Specialties

Cancer

Expert Tags

Cancer Stem Cells

Leukemias and Myelodisplasic Syndromes

Areas of Expertise

Molecular therapy

Transcriptional regulation

Microbiology & Immunology

Molecular and Cell Biology

Stem cell research

Expert Summary

Dr. Steidl studies the molecular and cellular mechanisms that lead to two related blood diseases, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His NIH-funded basic and translational research seeks to define the characteristics of pre-leukemic stem cells (pre-LSC), understand their progression to leukemic stems cells, and develop drug strategies to target the process. Dr. Steidl is co-director of the Albert Einstein Cancer Center's Blood Cancer Institute.
He was among the first researchers to demonstrate that MDS, a common precursor of AML, arises from defective blood-forming stem cells. As a result of his work, several experimental drugs targeting abnormal stem cells in patients with MDS and AML are in clinical trials.
In 2021, Dr. Steidl received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI) and a seven-year, $7 million grant for his research. He is author of more than 150 research papers, and has published studies in Nature, Nature Medicine, Cancer Cell, Nature Immunology, Nature Chemical Biology, Science Translational Medicine, and many others.

Research Profile

https://einsteinmed.edu/faculty/11118/Ulrich-Steidl

CHAM Provider

Off

Professional Title

M.D.

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/cf3e8062-d6d5-45c2-a8e3-7f38809ea…

Selected Publications

Selected recent publications (from a total of 176):
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, Verma A, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U. Genomic binding site restriction redirects pioneer transcription factor activity. Nat Genet. 2024 Sept 18; doi.org/10.1038/s41588-024-01911-7

Gao X*, Carpenter RS*, Boulais PE*, Zhang D, Marlein CR, Li H, Smith M, Chung DJ, Maryanovich M, Will B#, Steidl U#, Frenette PS#. Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis. Science. 2024 Aug 9; 385(6709):eadp2065.
Terrell JR, Taylor SJ, Schneider AL, Lu Y, Vernon TN, Xhani S, Gumpper RH, Luo M, Wilson WD, Steidl U#, Poon GMK#. DNA selection by the master transcription factor PU.1. Cell Rep. 2023; 42(7):112671.
Piszczatowski RT*, Schwenger E*, Sundaravel S, Stein CM, Liu Y, Stanley P, Verma A, Zheng D, Seidel RD, Almo SC, Townley RA#, Bülow HE#, Steidl U#. A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm. J Exp Med. 2022; 219(11):e20212552. 
Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 2021; 39:529-547 
Wheat JC, Sella Y, Willcockson M, Skoultchi AI, Bergman A, Singer RH, Steidl U. Single Molecule Imaging of Transcription Dynamics in Somatic Stem Cells. Nature. 2020; 583:431-436
Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A*, Steidl U*. Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level. Nat Med. 2019; 25:103-110
Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP Potentiates Multiple Oncogenic Signaling Pathways in AML. J Exp Med. 2018; 215:1709-1727
Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. Science Transl Med. 2018 Apr 11; 10:eaao3003
Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Tidorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GMK, Steidl U. Pharmacological Inhibition of the Transcription Factor PU.1 in Leukemia. J Clin Invest. 2017; 127:4297-4313
Stanley RF*, Piszczatowski RT*, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari SR, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.  A Myeloid Tumor Suppressor Role for NOL3.  J Exp Med. 2017; 214:753-771
Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. New IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia. Nat Chem Biol. 2015; 11:878-886
Will B*, Vogler TO*, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U. Minimal PU.1 Reduction Induces a Preleukemic State and Promotes Development of Acute Myeloid Leukemia. Nat Med. 2015; 21:1172-1181
Pandolfi A*, Stanley RF*, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U. PAK1 is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 2015; 126:1118-27
Bartholdy B*, Christopeit M*, Will B, Mo Y, Barreyro L, Yu Y, Bhagat TD, Okoye-Okafor UC, Todorova TI, Greally JM, Levine RL, Melnick A, Verma A#, Steidl U#. A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.      J Clin Invest. 2014; 124:1158-1167
Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U. Special AT-rich Sequence-Binding Protein 1 (Satb1) regulates hematopoietic stem cell self-renewal by promoting quiescence and repressing differentiation commitment. Nat Immunol. 2013; 14:437-45
Kawahara M*, Pandolfi A*, Bartholdy B*, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like Homeobox (HLX) Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. Cancer Cell. 2012; 22:194–208
Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally J, Ye BH, List A, Steidl C, Steidl U*, Verma A*. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations. Blood. 2012; 120:2076-2086
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. Overexpression of interleukin 1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012; 120:1290-1298
Roth M, Will B, Simkin G, Rao S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012; 120:386-394
Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoetin receptor agnoist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009; 114:3899-3908
 Review Articles and Commentaries:

Taylor SJ, Steidl U. Chemical restriction of PU.1 genomic binding sites activates alternate gene networks. Nat Genet. 2024; doi.org/10.1038/s41588-024-01912-6

Piszczatowski RT, Buelow HE, Steidl U. Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis. Blood. 2024; 143:2571-2587
Wheat JC, Steidl U. Posttranscriptional Arid3a Deregulation in AMKL. Blood. 2022; 139:637-638
Tatsumi G, Steidl U. Transcriptional circuit dynamics in HSPC. Blood. 2021; 138:1382-1384
Taylor SJ, Sundaravel S, Steidl U. Exploting a key transcriptional dependency: ZMYND8 and IRF8 in AML. Mol Cell. 2021; 81:3445-3446
Wheat JC, Steidl U. Gene expression at a single molecule level: Implications for MDS and AML. Blood. 2021; 138:625-636
Ueda K, Steidl U. Epigenetic Achilles' heel of AML. Nature Cancer. 2021; 2:481-483 Schwenger E, Steidl U. An evolutionary approach to clonally complex hematologic disorders. Blood Cancer Discov. 2021 May;2(3):201-215.
Sundaravel S, Steidl U. Stem cell origins of JMML. J Exp Med. 2021; 218:e20202152 
Stauber J, Greally JM, Steidl U. Preleukemic and leukemic evolution at the stem cell level. Blood. 2021; 137:1013-1018
Ueda K, Kumari R, Steidl U. Fueling clonal dominance through TRAFficking of NF-kB signaling. Nat Immunol. 2020; 21:489-490
Mitchell K, Steidl U. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). Cold Spring Harb Perspect Med. 2020; 10:a036251
Piszczatowski RT, Steidl U. Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy? Clin Cancer Res. 2019; 25:4868-4870
Chen J, Steidl U. Inhibition of HIF1α Signaling: A Grand Slam for MDS Therapy ? Cancer Discovery. 2018; 8:1355-1357
Wheat JC, Steidl U. Linking histone methylation, transcription rates, and stem cell robustness. Haematologica. 2018; 103:1093
Taylor SJ, Steidl U. Metabolic strugGLS after FLT3 inhibition in AML. Blood. 2018; 131:1631-1632
Wheat JC, Steidl U.  ETO2-GLIS2: A chimeric transcription factor drives leukemogenesis through a neomorphic transcription network. Cancer Cell. 2017; 31:307-308
Shastri A, Will B, Steidl U*, Verma A*. Stem and Progenitor Cell Alterations in Myelodysplastic Syndromes. Blood. 2017; 129:1586-1594
Carvajal L, Steidl U. Eliminating cancer stem cells in CML with combination transcriptional therapy. Cell Stem Cell. 2016; 19:6-8 
Stanley RF, Steidl U. Molecular mechanism of mutant CALR-mediated transformation. Cancer Discovery. 2016; 6:344-346
Stanley RF, Steidl U. Ectopic Dnmt3b Expression Delays Leukemogenesis. Blood. 2016; 127:1525-6
Antony-Debre I, Steidl U. Functionally relevant RNA helicase mutations in familial and sporadic myeloid malignancies. Cancer Cell. 2015; 27:609-611
Verma A, Steidl U. A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Nat Med. 2015;21:113-114
Will B, Steidl U. Combinatorial haplo-deficient tumor suppression in 7q-deficient myelodysplastic syndrome and acute myeloid leukemia. Cancer Cell. 2014; 25:555-557
Will B, Steidl U. Stem cell fate regulation by dynein motor protein Lis1. Nat Genet. 2014; 46:217-218
Antony-Debre I, Steidl U. CDK6, a new target in MLL-driven leukemia. Blood. 2014; 124:5-6
Elias HK, Schinke C, Bhattacharyya S, Will B, Verma A, Steidl U. Stem cell origin of myelodysplastic syndromes. Oncogene. 2013 Dec 16. doi: 10.1038/onc.2013.520
Pandolfi A, Barreyro L, Steidl U. Pre-leukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med. 2013; 2:143–150

Is Open Scheduling

Off

David M. Loeb

Read more about David M. Loeb

David M. Loeb

https://assets.montefioreeinstein.org/profiles/images/Loeb_David_MD_2x.jpg

Provider

Faculty

Expert

First Name

David

Last Name

Loeb

NPI

1841236676

Faculty ID

15556

CMO Specialties

Pediatric Hematology-Oncology

Clinical Terms

Myelodysplastic Syndromes

Ankle Pain

Chronic Lymphocytic Leukemia

Thrombocytopenia

Suicidal Thoughts

Hospital-Associated Pneumonia

Acute Lymphoblastic Leukemia

Hypertensive Emergency

Abnormal Uterine Bleeding

Knee Pain

Chronic Constipation

CMV Infection

Urinary Tract Infection

Acute Respiratory Distress Syndrome

Hydronephrosis

Unresolved or Complicated Grief

Bone Marrow Transplant

Headaches in Children

Diabetic Peripheral Neuropathy

Mucositis

Boil

Headache

Numbness And Tingling

Grief

Lung Nodules

Secondary Adrenal Insufficiency

Fever

Addison's Disease

Opioid Overdose

Clostridium Difficile Colitis

Secondary High Blood Pressure

Painful Urination

Blood In Stool

Embolism And Thrombosis

Acute Pancreatitis

Deep Vein Thrombosis (DVT)

Elevated Blood Pressure

Hemorrhoids

Congenital Hydrocephalus

Disruptive Behavior Disorder

Peripheral Neuropathy

Abdominal Pain

Electrolyte Imbalance

Employment Status

Full Time

Patient Type

Pediatric

Department

einstein-dept-pediatrics

einstein-dept-developmental-molecular-biology

Gender

Male

david.loeb@einsteinmed.edu

Phone

718-920-4664

Titles

Type

Academic

Department

Department of Pediatrics

Department Link

Rank

Professor

Division

Pediatric Hematology-Oncology

Type

Academic

Department

Department of Developmental & Molecular Biology

Department Link

Rank

Professor

Type

Clinical

Title

Chief, Division of Pediatric Hematology, Oncology, and Cellular Therapy

Type

Clinical

Title

Director, Sarcoma Program

Type

Clinical

Title

Professor, Pediatrics and Developmental and Molecular Biology

Tags

me-patientcare-cancer-research-cdtmi

me-patientcare-cancer-research-cdtmi-members

Type

Administrative

Title

Chief, Division of Pediatric Hematology / Oncology, Department of Pediatrics

Type

Administrative

Title

Linda and Earle Altman Faculty Scholar in Cancer Research

Locations

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.87885 40.88037)

Address Line 1

3415 Bainbridge Avenue

City

Bronx

State

Zip

10467-2403

Location Title

The Children's Hospital at Montefiore

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.878214 40.879949)

Room

910

Address Line 1

Montefiore Medical Center

Address Line 3

3411 Wayne Avenue

City

Bronx

State

Zip

10467

Location Title

Montefiore Medical Center

Education and Trainings

Education Type Label

Medical Education

Education Institution

Columbia University

Education Type Label

Fellowship

Education Institution

Johns Hopkins University

Education Type Label

Residency

Education Institution

Johns Hopkins University

Professional Interests

Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis.  His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process.  More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma migration, invasion, and metastasis.  Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA. More recently, the laboratory has developed an interest in targeting the metabolic reprogramming associated with metastasis as a way to prevent the outgrowth of distant metastases from disseminated tumor cells.
 
Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3.  He serves as the local PI for a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors.  Finally, as an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.

Research Areas

Dr. Loeb has a translational research laboratory focused on the biology and treatment of bone tumor metastasis, especially the role of Wnt signaling pathways. Other areas of interest include the role of the RNA helicase, DDX3, in bone sarcomas and the met

Specialties

Expert Tags

Bone Marrow Transplant

Areas of Expertise

Childhood cancer

Treatments for childhood cancer including bone marrow transplant

Musculoskeletal Tumors

Sarcoma

Expert Summary

Dr. Loeb is a leading pediatric oncologist and NIH-funded researcher. He has extensive expertise in sarcoma research and clinical care and is a bone marrow transplantation specialist. Dr. Loeb’s research spans the spectrum from basic and translational studies to clinical trials using novel therapies.

Research Profile

https://einsteinmed.edu/faculty/15556/David-Loeb

Clinical Profile

https://montefioreeinstein.org/profiles/1841236676/david-m-loeb

CHAM Provider

Professional Title

M.D.

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/9bfd753a-1293-4fdf-ac41-fd352bc7d…

Selected Publications

Dr. Loeb's PubMed bibliography can be found here:  
<a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fiIspwqfwUE46/bibliography/5…;

EMR ID

6405

Biography

David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer.Dr. Loeb earned his Bachelor of Arts in biology in 1987 at Johns Hopkins University. In 1993, he received his Doctor of Philosophy in Pathology and, in 1994, his Doctor of Medicine at Columbia University. In 1994, he also began an internship in Pediatrics at the Johns Hopkins University School of Medicine, followed by a residency in 1995 and a fellowship in Pediatric Hematology Oncology at the same institution.Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis and has used this model to perform preclinical testing of novel agents that can interfere with this process. One area of focus is the metabolic differences between cancer cells and normal cells, and between metastases and the primary tumor, with the intention of targeting these differences therapeutically. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma and osteosarcoma migration, invasion and metastasis. Dr. Loeb also studies the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA.Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He has also directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Stemming from his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents and young adults with sarcomas. Dr. Loeb’s original research, based on his clinical and laboratory studies, has been published in multiple journals and books.Dr. Loeb has been a recipient of many awards, including the Director’s Teaching Award in Clinical Science from Sidney Kimmel Comprehensive Cancer Center in 2006, 2010 and 2015, and The Justin Straus Chordoma Research Award in 2009.

Is Open Scheduling

Off

Alyson B. Moadel-Robblee

Read more about Alyson B. Moadel-Robblee

Alyson B. Moadel-Robblee

https://assets.montefioreeinstein.org/profiles/images/Moadel_Roblee_Alyson_PhD_2x.jpg

Faculty

Expert

First Name

Alyson

Last Name

Moadel-Robblee

Faculty ID

479

Patient Type

Adult

Department

einstein-dept-epidemiology-population-health

einstein-dept-medicine

einstein-dept-radiation-oncology

einstein-dept-psychiatry-behavioral-sciences

alyson.moadel-robblee@einsteinmed.edu

Phone

718-430-2696

Titles

Type

Academic

Department

Department of Epidemiology & Population Health

Department Link

Rank

Professor

Division

Health Behavior Research & Implementation Science

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Type

Academic

Department

Department of Radiation Oncology

Rank

Professor

Type

Academic

Department

Department of Psychiatry and Behavioral Sciences

Department Link

Rank

Professor

Type

Administrative

Type

Administrative

Title

Division Head, Division of Health Behavior Research & Implementation Science, Department of Epidemiology & Population Health

Tags

me-patientcare-cancer-research-epidemiology

Type

Administrative

Title

Founding Director, Bronx Oncology Living Daily (BOLD) / Psychosocial Oncology Program

Type

Administrative

Type

Administrative

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Belfer Building

Room

1006

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

Alyson Moadel-Robblee, Ph.D. is Clinical Professor in the Department of Epidemiology & Population Health at the Albert Einstein College of Medicine. She holds several roles including Director of the Psychosocial Oncology Program, founding Director of the Bronx Oncology Living Daily (BOLD) Program, and Co-Director of the Integrative Oncology Program of the Montefiore Einstein Center for Cancer Care (MECCC), Bronx NY. As a health psychologist, Dr. Moadel applies a career in research, teaching and counseling to her interest in the psychological and social factors associated with coping with cancer. She received her doctorate in Health Psychology from Yeshiva University in 1995, after which she received her postdoctoral training (1995-1997) at Memorial Sloan-Kettering Cancer Center in Psycho-Oncology. Since then, she has been involved in studying the efficacy of various behavioral and mind-body intervention methods to improve the quality of life of cancer patients.

Specialties

Cancer

Expert Tags

Community Engagement

Areas of Expertise

Psychosocial support for adult cancer patients

Emotionally and mentally preparing for cancer treatments and survivorship

Novel support programs for those impacted by cancer and tips for patients and loved ones on how to cope with the disease

Research on cancer management (e.g. impact of yoga of cancer survivorship)

Expert Summary

Dr. Moadel-Robblee is a health psychologist who leads programs designed to help patients and their families cope with the psychological and emotional effects of cancer and cancer treatment. Her Bronx Oncology Living Daily (B.O.L.D. Living) program offers a variety of free support, educational, and mind-body workshops designed to empower and nurture cancer patients, survivors, and loved ones. Workshops feature fitness/nutrition, mind-body programs, creative arts and more.

Research Profile

https://einsteinmed.edu/faculty/479/Alyson-Moadel-Robblee

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/57f7e379-ce8f-46d1-83a6-d9839ad58…

Is Open Scheduling

Off

Amit K. Verma

Read more about Amit K. Verma

Amit K. Verma

https://assets.montefioreeinstein.org/profiles/images/Verma_Amit_MD_2x.jpg

Provider

Faculty

Expert

First Name

Amit

Last Name

Verma

NPI

1033299524

Faculty ID

10065

CMO Specialties

Hematology

Myelodysplastic Syndrome

Clinical Terms

Monoclonal Gammopathy Of Unknown Significance

Bone Biopsy

Anemia Of Chronic Disease

Iron Deficiency Anemia

Folate Deficiency Anemia

Hemochromatosis

Thrombophlebitis

Swollen Lymph Nodes

Splenic Sequestration

Vitamin B12 Deficiency Anemia

Macroglobulinemia

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Hemarthrosis

Henoch Schonlein Purpura

Aplastic Anemia

Petechiae

Purpura

Acquired Von Willebrand Disease

Myelodysplastic Syndromes

Sickle Cell Dactylitis

Anemia During Pregnancy

Deep Vein Thrombosis (DVT)

Superficial Thrombophlebitis

Paradoxical Embolism

Hodgkin Lymphoma

Antiphospholipid Syndrome

Pulmonary Embolism

Neutropenia

Disseminated Intravascular Coagulation

Acute Promyelocytic Leukemia

Blood Donation

Fanconi Anemia

Heparin-Induced Thrombocytopenia

Anemia Of Prematurity

Acute Lymphoblastic Leukemia

Axillary Lymph Node Dissection

Lobular Carcinoma In Situ

Multiple Myeloma

Sarcoma

Bone Biopsy

Lambert-Eaton Syndrome

Soft Tissue Sarcomas

Small Cell Lung Cancer

Ovarian Cancer

Stem Cell Transplant

Chronic Lymphocytic Leukemia

Carcinoid Syndrome

Cervical Cancer

Metastatic Melanoma

Stereotactic Radiation Therapy

Bladder Cancer

Myelodysplastic Syndromes

Squamous Cell Carcinoma In Situ

Esophageal Cancer

Non-Small Cell Lung Cancer

Lymphedema

Kidney Cancer

Platelet Transfusion

Oncology Discharge Instructions

Leukopenia

Adenomatous Polyps

Metastatic Brain Cancer

Testicular Cancer

Head And Neck Cancer

Intrathecal Injection

Hodgkin Lymphoma

Familial Adenomatous Polyposis

Acute Promyelocytic Leukemia

Locally Advanced Prostate Cancer

Inflammatory Breast Cancer

Squamous Cell Skin Cancer

Tumor Ablation

Acute Lymphoblastic Leukemia

Chronic Myelogenous Leukemia

External Beam Radiation Therapy

Paget's Disease Of The Breast

Bone Marrow Transplant

Androgen Deprivation Therapy

Acute Myelogenous Leukemia

Employment Status

Full Time

Patient Type

Adult

Department

einstein-dept-oncology

einstein-dept-medicine

einstein-dept-developmental-molecular-biology

Languages

Hindi

Punjabi

Gender

Male

amit.verma@einsteinmed.edu

Phone

718-430-8761

Titles

Type

Academic

Department

Department of Oncology

Rank

Professor

Division

Medical Oncology

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Oncology & Hematology

Type

Academic

Department

Department of Developmental & Molecular Biology

Department Link

Rank

Professor

Type

Clinical

Title

Interim Chair, Department of Oncology

Tags

me-patientcare-medicaloncology

Type

Clinical

Title

Associate Director, Translational Science, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-research-cdtmi-members

me-patientcare-cancer-clinical-blood-bone-marrow

Type

Clinical

Title

Director, Myelodysplastic Syndromes (MDS) Program

Type

Clinical

Title

Director, Hemato-Oncology

Tags

me-patientcare-cancer-clinical-aids-malignancies

Type

Clinical

Title

Co-Director, Blood Cancer Institute

Tags

bci-leaders

Type

Clinical

Title

Professor, Department of Medicine (Oncology)

Type

Clinical

Title

Professor, Department of Developmental & Molecular Biology

Type

Clinical

Type

Administrative

Title

Director, Division of Hemato-Oncology, Montefiore Department of Oncology

Tags

me-patientcare-cancer-research-stem-cell-cancer-biology

Type

Administrative

Title

Associate Director, Translational Science, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-research-cancerdormancy-clinicalresearchco-leaders

me-patientcare-cancer-about-associate-directors

Type

Administrative

Title

Interim Chair, Department of Oncology

Type

Administrative

Title

Susan Resnick Fisher Academic Chair in Brain Cancer Research

Locations

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.84475 40.84623)

Address Line 1

1695 Eastchester Road

City

Bronx

State

Zip

10461

Location Title

Montefiore Medical Park at Eastchester

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.84563 40.84596)

Address Line 1

1575 Blondell Avenue

City

Bronx

State

Zip

10461-2601

Location Title

Montefiore Medical Park at 1575 Blondell

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Chanin Building

Room

302B

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Education and Trainings

Education Type Label

Medical Education

Education Institution

All-India Institute of Medical Sciences

Education Type Label

Fellowship

Education Institution

University of Illinois at Chicago

Education Type Label

Fellowship

Education Institution

Northwestern University Medical School

Education Type Label

Residency

Education Institution

University of Illinois at Chicago

Professional Interests

https://einsteinmed.edu/labs/amit-verma/
Targeting signal transduction in hematologic malignancies:  Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways. 
Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms:  We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML. 
Epigenomic analysis of tumors: We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.
Clinical studies in Myelodysplastic syndromes: We have a “center of excellence” clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.

Research Areas

Myelodysplastic syndrome (MDS) are hematologic malignancies characterized by ineffective hematopoiesis. We study the molecular pathogenesis of MDS to identify targetable pathways for treatment of this disease.

Specialties

Cancer

Expert Tags

Blood Cancer

AML/MDS

Areas of Expertise

Blood cancer detection & treatment

9/11 associated cancers

COVID-19 & cancer

Expert Summary

Dr. Verma is a blood cancer expert, who specializes in the research and treatment of blood cancers.

Research Profile

https://einsteinmed.edu/faculty/10065/Amit-Verma

Clinical Profile

https://montefioreeinstein.org/profiles/1033299524/amit-k-verma

CHAM Provider

Off

Professional Title

M.B.B.S.

Clinical Focus

Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients.

Research Focus

Dr. Verma conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/cd9afe6a-e5ff-4a4a-a6d9-47609d6c7…

Lab Website Link

https://einsteinmed.edu/labs/amit-verma

Selected Publications

<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40424086/" target="_blank">Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.</a> Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, Verma A. J Clin Invest. 2025 May 27. PMID: 40424086.</li>

<li><a href="https://pubmed.ncbi.nlm.nih.gov/40333990/" target="_blank">Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.</a> Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* Verma A,* Salomonis N.* Sci Transl Med. 2025 May 7. PMID: 40333990. *Co Corresponding</li>

<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39316768/" target="_blank">A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.</a> 
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, Verma A. 
Blood. 2024 Sep 24.PMID: 39316768 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39300320/" target="_blank">Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.</a> 
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A*, Konopleva M*. 
Nat Cancer. 2024 Sep 19. PMID: 39300320 
*CoCorresponding </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39294495/" target="_blank">Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.</a> 
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, Verma A, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U. 
Nat Genet. 2024 Sep 18. PMID: 39294495 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/38521065/" target="_blank">Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.</a> 
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, Verma A, Neugebauer KM, Pillai MM. Mol Cell. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065 </li>
<li> Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, Verma A^ Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency JCI, 2024 Feb 20 PMID: 38376944 </li>
<li> Thakkar A, Pradhan K, Duva B, Carreño JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, Verma A*, Halmos B*  Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial  Elife 2023, Mar 28;12:e83694. PMID: 36975207 </li>
<li> Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. PMID: 37341641. </li>
<li> Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, Verma A*. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103. </li>
<li>Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, Verma A. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nat Med. 2022 Mar 7. PMID: 35256801.</li>
<li>Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, Verma A. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Cancer Cell. 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706</li>
<li>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, Verma A*, Halmos B*. *Co-Corresponding Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.</li>
<li>Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 Feb 26. PMID: 35220402.</li>
<li>Pinho S, Wei Q, Maryanovich M, Zhang D, Balandrán JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK, Verma A, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. Nat Cell Biol. 2022 Feb 24. PMID: 35210567.</li>
<li>Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, Verma A, Greally JM, Raj SM, Goel S, Ali SM. The Genomics of Colorectal Cancer in Populations with African and European Ancestry. Cancer Discov. 2022 Feb 17: PMID: 35176763.</li>
<li>Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, Verma A*, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. Cell Rep. 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.</li>
<li>Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A*, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding</li>
<li>Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.</li>
<li>Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, Verma A, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production Dev Cell, 2021, Mar 8;56(5):627-640. PMID: 33651979.</li>
<li>Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Verma A, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. PMID: 33846558.</li>
<li>Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy Nature Cancer, 2021, 2: 392–399.</li>
<li>Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, Verma A*. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.</li>
<li>List AF, Sun Z, Verma A*, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin JCO, 2021, Jan 13: PMID: 33439748 *Corresponding.</li>
<li>COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.</li>
<li>Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.</li>
<li>Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337</li>
<li>Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-151. PMID: 31914241</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,  Verma A*. Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts Elife, Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852</li>
<li>Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D* 
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies. Nature Cell Bio 2019 May;21(5):640-650 * Equal Contribution </li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,* Wickrema A* 
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis Cancer Discovery 2019 Jun;9(6):778-795 * Equal Contribution</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,  Verma A*. Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts Elife, Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852</li>
<li>Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D* 
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies. Nature Cell Bio 2019 May;21(5):640-650 * Equal Contribution </li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,* Wickrema A* 
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis 
Cancer Discovery 2019 Jun;9(6):778-795 * Equal Contribution</li>
<li>Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level Nature Medicine 2018, Jan;25(1):103-110 * Equal Contribution</li>
<li>Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.  Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B. Verma, A. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 Sep 25. PMID: 30252677</li>
<li>Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A*, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018 Aug 13. PMID: 30104217 * Equal Contribution</li>
<li>Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A*, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster JAMA Onc, 2018 Jun 1;4(6):821-827. PMID: 29710195  * Equal Contribution</li>
<li>Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018 Sep 12;10(458). PMID: 30209246</li>
<li>Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018 Jul 25;3(14). PMID: 30046005</li>
<li>Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. Sci Transl Med. 2018, Apr 11;10(436). PMID: 29643228</li>
<li>Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.  IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med. 2018 Jun 4;215(6):1709-1727 PMID: 29773641</li>
<li>Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A, “Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,”  Genome Res, 2017, Oct 6. PMID: 28986391</li>
<li>Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,  Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A, “Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,” Cancer Research Jul, 2017, PMID: 28684528</li>
<li>Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Direct “Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,”  Cancer Cell 2017 Oct 9.PMID: 29017059 </li>
<li>Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., “Pharmacological inhibition of the transcription factor PU.1 in leukemia,”  J Clin Invest 2017 Oct 30, PMID: 29083320</li>
<li>Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, Verma A*, Epling-Burnette PK* (*Co-Corresponding), “Efficacy of ALK5 Inhibition in Myelofibrosis.”   JCI Insight (In Press)</li>
<li>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A*, Susztak K* (*Co-Corresponding), “Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .”  JBC 2016, Dec 1. PMID: 2790905</li>
<li>Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,  Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A,  “Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.”  Cancer Res 2016 Jun 10. PMID: 27287719</li>
<li>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,  Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I, Verma A, “High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,”  Leukemia 2016 Apr 29. PMID: 27125205</li>
<li>Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. “MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.”  Nat Commun. 2016 Feb 22;7:10739. PMID: 26898884</li>
<li>Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., “Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.”  Lancet Haematol. 2015 Oct;2(10):e417-26. PMID: 26686043</li>
<li>Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*, Verma A*, Wickrema A*. (*Co-Corresponding),  “Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.”  PNAS 2015; Nov 17;112(46): PMID: 26578796</li>
<li>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U., “New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.’ Nature Chem Biol. 2015 Oct 5. PMID: 26436839</li>
<li>PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U, “PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.” Blood. 2015 Jul 13. PMID: 26170031</li>
<li>Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, “Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.” Br J Haematol. 2015 Jun 24. PMID: 26105212</li>
<li>Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E, “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.” Mol Cell. 2015 Jun 3. PMID: 26051178</li>
<li>Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC, “Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma  Cells.” Mol Cell Biol. 2015 May 26. PMID: 26012550</li>
<li>Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC, “Central Role of ULK1 in Type I Interferon Signaling.” Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232</li>
<li>Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I, “TET1 is a tumor suppressor of hematopoietic malignancy.” Nat Immunol. 2015 Apr 13. PMID: 25867473</li>
<li>Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*,   *co-corresponding authors, “IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.” Blood. 2015, Mar 25. PMID: 25810490               </li>
<li>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, “Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.” Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665 </li>
<li>Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, “Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.” Blood. 2015 Jan 8. PMID: 25573988</li>
<li>Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U, “Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.” Nature Medicine, 2015 (In Print)</li>
<li>Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A, “Targeting chemokine pathways in esophageal adenocarcinoma.” Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576</li>
<li>Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A, “Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.” Clin Cancer Res. 2014 Jun 10. PMID: 24916699</li>
<li>Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA, “TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.” Cell Rep. 2014 May 14. PMID: 24835990</li>
<li>Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., “Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.” Blood. 2014 Jun 2. PMID: 24891322</li>
<li>Tamari R,  Schinke C, Bhagat T, Roth M, Braunschweig I,  Will B,  Steidl U, Verma A, “Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.” Leuk Lymphoma, 2014 Dec;55(12):2901-6.PMID: 24650011</li>
<li>Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U, *Co-Corresponding, “A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.” Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588</li>
<li>Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, “High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.”      Oncogene, 2014 Mar 31 PMID: 24681958</li>
<li>Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.”Leukemia 2014 Jan 16. PMID: 24429498</li>
<li>Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, “Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.” Cell Reports 2013 Dec 24 PMID: 24373966</li>
<li>Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K, “Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.” Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934</li>
<li>Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M,  Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, “Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.” JCO 2013 Oct 1;31(28):3557-64. PMID: 24002510</li>
<li>Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK,  “Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.”  Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763</li>
<li>Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y, “Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.” Gut 2013 Sep 2. PMID: 24000294 </li>
<li>Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K, *Co-Corresponding,  “High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.” Genes Chromosome Cancer 2013 Oct 3. PMID: 24123713</li>
<li>Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC, “Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.”  JBC, 2013 Aug 16;288(33):23814-22 PMID: 23814052</li>
<li>Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A;  “Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.” Nucleic Acid Res 2013  Sep;41(16):e157 PMID: 23861445</li>
<li>Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U, “Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.” Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689</li>
<li>Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A,  “miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.” Blood 2013, Apr 11;121(15):2875-81. PMID: 23390194</li>
<li>Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A, “High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.” JBC 2013 Mar 29;288(13):8805-14. PMID: 23306203</li>
<li>Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S,* Co-Corresponding, “Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.”  Journal of Immunology 2013 Mar 15;190(6):2966-75. PMID: 23408834</li>
<li>Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ*, Co-Corresponding, “Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett’s Esophagus and Esophageal Adenocarcinoma.” Gastroenterology 2013 May;144(5):956-966. PMID: 23333711</li>
<li>Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A,  “Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.” Cancer Res, 2012 Dec 27. PMID: 23066032</li>
<li>Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,  Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A,  “Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.” Blood 2012; 120(10):2076-86. PMID: 22753872</li>
<li>Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, “Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.” Leukemia. 2012 Sep 11. PMID: 23032694</li>
<li>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U, “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.” Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552</li>
<li>Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,  “Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.”   Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315</li>
<li>Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U., “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.” Blood. 2012 May 24. PMID: 22627766</li>
<li>Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A., “Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.” Leuk Lymphoma.2012 Apr 18.  PMID: 22448921</li>
<li>Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.”   Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540</li>
<li>Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC, “Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.” J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535</li>
<li>Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A,  “Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.” J Biol Chem. 2011 Apr 30. PMID: 21532034 </li>
<li>Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A, “Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.” PLOS Genetics 2011 Mar;7(3) PMID: 21483804</li>
<li>L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,  G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma, “Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.” Cancer Research 2011 Feb 1;71(3):955-63.PMID: 21189329</li>
<li>Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC, “Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.”   
J Biol Chem. 2011 Feb 25;286(8):6017-26.PMID: 21149447</li>
<li>Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC, “Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.” J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.</li>
<li>Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B, “Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.”  
Leuk Lymphoma. 2010 Jun;51(6):1108-14. PMID: 20536349</li>
<li>Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.” Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039</li>
<li>Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J, “Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.” Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779</li>
<li>Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A, Barzilai N, Greally JM, “Cytosine methylation dysregulation in neonates following intrauterine growth restriction.” PLoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273</li>
<li>Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M., “High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.” Nucleic Acids Res. 2009 Jul;37(12):3829-39.   PMID: 19386619</li>
<li>Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A, “Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.” PLOS One 2008 Aug 13;3(8):e2965    PMID: 18698424</li>
<li>Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,   Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,  Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A, “Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.”       Blood 2008 Oct 15;112(8):3434-43  PMID: 18474728</li>
<li>Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A, “Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.”  Leukemia and Lymphoma 2008 Oct;49(10):1963-75</li>
<li>Zhou L, Opalinska J, Verma A, “p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.” Cell Cycle 2007, 1;6(5):534</li>
<li>Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A, “Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.” Blood 2006, 15;108(13):4170-7</li>
<li>Verma A, and List A, “Cytokine Targets in Myelodysplastic syndromes.” Current Hematology Reports 2005 Nov;4(6):429-35</li>
<li>Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN, “Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.” Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8</li>
<li>Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, “Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.”  Bone Marrow Transplant. 2003 May;31(9):813-6.</li>
<li>Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., “Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.”  Journal of Biological Chemistry 22;277(47):44988-95</li>
<li>Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., “Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.” Journal of Immunology 2002, 168 (12) (Cutting edge section)</li>
<li>Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, “Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.” Journal of Biological Chemistry 2002, 277(10):7726-35</li>
<li>Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K, “Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.” Blood  2002, 99(6):2255-8</li>
</ol>
Review articles
<ol start="1" type="1">
<li>Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A, “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.” Leukemia, 2015 (In Press)</li>
<li>Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A., "Role of DNA methylation in renal cell carcinoma." J Hematol Oncol. 2015 Jul 22;8(1):88. PMID: 26198328</li>
<li>Verma A, Steidl U., “A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.”  
Nat Med. 2015;21:113-4.  PMID: 25654599</li>
<li>Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes." Leukemia. 2015 Mar 12. PMID: 25761935</li>
<li>Shenoy N, Vallumsetla N,  Rachmilewitz E, Verma A, Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome." Blood, 2014 Aug 7;124(6):873-81. PMID: 24923296</li>
<li>Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK,    Evans T.,  "Retinoic acid signaling pathways in development and diseases." 
Bioorg Med Chem. 2014 Jan 15;22(2):673-83. PMID: 24393720</li>
<li>Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*,  Steidl U* *CoCorresponding,    “Stem cell origin of myelodysplastic syndromes.” Oncogene 2013 Dec 16. PMID: 24336326</li>
<li>Pathak S, Roth M, Verma A*, Steidl U*.  *CoCorresponding,    “Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.” 
Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. PMID: 24215532</li>
<li>Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK,  “Linked-in: design and efficacy of antibody drug conjugates in oncology.” Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630</li>
<li>Khan H, Vale C, Bhagat T, Verma A.,   “Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.” 
Semin Hematol. 2013 Jan;50(1):16-37. PMID: 23507481</li>
<li>Elias H, Verma A,  “Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.” 
Leuk Lymphoma. 2012 Dec;53(12):2337-8. PMID: 22897726</li>
<li>Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A.,  “Alterations in the ribosomal machinery in cancer and hematologic disorders.” J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827</li>
<li>Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A.,  “Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.” Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291</li>
<li>Sharma A,  Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A,  “DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.” WIREs Systems Biology and Medicine 2010 Nov-Dec;2(6):654-69. PMID: 20890963</li>
<li>Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A,  “Aberrant DNA methylation in malignant melanoma.” Melanoma Research 2010, Aug; 20(4):253-65 PMID: 20418788</li>
<li>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A., “Mechanism of action of lenalidomide in hematological malignancies.” 
J Hematol Oncol. 2009 Aug 12;2:36</li>
<li>Opalinska J, Zhou L, Verma A., “A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.” Leukemia Research (Commentary) 2007, 48(3):443</li>
<li>Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A., “Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.” Journal of Interferon and Cytokine Research 2007, 27(7):543</li>
<li>Mohindru M, Verma A,  “Engineered antibodies act as targeted therapies in cancer treatment.” Indian Journal of Pediatrics, 2005 Nov;72(11):943-7</li>
<li>Sassano A, Verma A, Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling." Methods Molecular Medicine, 2005;116:135-50.</li>
<li>Mohindru M, Verma A, "Kinase inhibitors translate lab discoveries into exciting new cures for cancers." Indian Journal of Pediatrics, 2004 Aug;71(8):713-8.</li>
<li>Verma A, Kambhampati S, Parmar S, Platanias LC,  “Jak family of kinases in cancer.” Cancer Metastasis Rev. 2003 Dec;22(4):423-34.(rev)</li>
<li>Verma A, and Platanias LC, “Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.” Leukemia and Lymphoma  2002, 44:703-709</li>
<li>Verma A, and Stock W, “Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.” Current Opinion in Oncology, 2001, 13:14-20</li>
<li>Verma A, and Gupta YK,  “The search for a super oral rehydration solution (0RS).” Drugs: News and Views, 1995, 3(2):129-132. </li>
</ol>

EMR ID

4772

Biography

Amit K. Verma, MD, is Interim Chair, Department of Oncology, Associate Director of Translational Science, Montefiore Einstein Comprehensive Cancer Center, Professor, Medical Oncology and Professor, Developmental & Molecular Biology, Albert Einstein College of Medicine.Dr. Verma earned his Doctor of Medicine at the All India Institute of Medical Sciences in 1995 and finished his training in internal medicine, hematology oncology and stem cell transplantation at the University of Illinois and Northwestern University in 2003.Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients. He conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.Dr. Verma is a scholar of the Leukemia and Lymphoma society, elected member of American society of clinical investigation and his research is funded by the NIH, Department of Defense, American Cancer Society, Edward P. Evans Foundation and various other private foundations.

Is Open Scheduling

Off

Brendon M. Stiles

Read more about Brendon M. Stiles

Brendon M. Stiles

https://assets.montefioreeinstein.org/profiles/images/Stiles_Brendon_MD_2x.jpg

Provider

Faculty

Expert

First Name

Brendon

Last Name

Stiles

NPI

1013176387

Faculty ID

16884

CMO Specialties

Cardiothoracic Surgery

Cardiothoracic Surgery (Thoracic)

Lung Cancer

Non-small Cell Lung Cancer

Small Cell Lung Cancer

Esophageal Cancer

Cancer

Clinical Terms

Hyperhidrosis, Focal, Primary

Excision of Mediastinal Cyst

Solitary Lung Nodule

Lobectomy, Lung, Robot Assisted

Thymectomy with VATS

Lung Volume Reduction Surgery

DaVinci Robotic Surgery

Lung Metasteses

Mesothelioma

Excision of Mediastinal Tumor

Thymectomy, Robot Assisted

Plication Of The Diaphragm

Pleurectomy and Decortication

Paraesophageal Hernia

Cancer of Esophagus

Mediastinal Mass Resection

Eophageal Diverticulum

Esophageal Cancer

Eophagectomy, Laparoscopic

Pulmonary Nodules

Excision, Neoplasm, Chest Wall

Resection, Lung, Wedge, Thoracoscopic

Hyperhidrosis

Lung Cancer - Diagnostic Testing

Hiatal Hernia

Excision of Chest Wall Tumor

Minimally Invasive Lung Surgery

Benign Esophageal Disease

Minimal Access Surgery - GERD

Malignant Neoplasm of Anterior Mediastinum

Lung Nodules

Laparoscopic Nissen Fundoplication

Repair, Hernia, Hiatal, Laparoscopic

Extrapleural Pneumonectomy

Lobectomy, Lung, Using VATS

Surgical Removal of Thymona

Thorascopic Lung Surgery

Thoracotomy

Resection, Pancoast Tumor, Rib and Chest Wall

Excision, Esophagus, Combined Laparoscopic and VATS Approach

Thymectomy

Esophageal Surgery

Lobectomy

Benign Tumor of Mediastinum

Segmentectomy

Repair, Hernia, Hiatal, Paresophageal

Surgical Removal of Pancoast Tumor involving Rib and Chest Wall

Minimally Invasive Robotic Surgery

Esophagectomy

Lung Metastasis

Screening Computed Tomography for Coronary Artery Disease and Lung Cancer

Lung Cancer

Surgical Management of Lung Cancer

Pneumonectomy

Esophagectomy, Robot-Assisted, Laparoscopic

Thoracic Outlet Syndrome

Secondary Cancer of Lung

Minimally Invasive Surgery

Management of Lung Nodules

Esophageal Cancer Surgery

Lung Biopsy

Esophagomyotomy, Laparoscopic

Lung Surgery

Employment Status

Full Time

Patient Type

Adult

Department

einstein-dept-cardiothoracic-vascular

einstein-dept-oncology

einstein-dept-medicine

Gender

Male

brstiles@montefiore.org

Phone

718-920-5732

Titles

Type

Academic

Department

Department of Cardiothoracic & Vascular Surgery

Rank

Professor

Type

Academic

Department

Department of Oncology

Rank

Professor

Division

Medical Oncology

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Oncology & Hematology

Type

Clinical

Title

Chief, Divisions of Thoracic Surgery & Surgical Oncology

Type

Clinical

Title

Associate Director, Surgical Oncology, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-clinical-gastrointestinal

Type

Clinical

Title

Professor, Cardiothoracic Surgery

Type

Administrative

Title

Associate Director, Surgical Oncology, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-about-directors-deputy-directors

me-patientcare-cancer-research-cdtmi-members

Locations

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.88429 40.96992)

Address Line 1

1088 North Broadway

City

Yonkers

State

Zip

107

Location Title

St. John's Riverside Boyce

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8614 41.01444)

Address Line 1

128 Ashford Avenue

City

Dobbs Ferry

State

Zip

10522-1924

Location Title

St. Johns Riverside Hospital Dobbs Ferry

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.88072 40.88002)

Address Line 1

111 East 210th Street

City

Bronx

State

Zip

10461-2401

Location Title

Montefiore Medical Center

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.88521 40.96784)

Address Line 1

967 North Broadway

City

Yonkers

State

Zip

10701-1301

Location Title

St. John's Riverside Hospital

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.92481 41.09677)

Address Line 1

160 North Midland Avenue

City

Nyack

State

Zip

10960-1912

Location Title

Montefiore Nyack Hospital

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.76857 41.02698)

Address Line 1

41 East Post Road

City

White Plains

State

Zip

10601-4622

Location Title

White Plains Hospital

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8785732 40.879979)

Address Line 1

Montefiore Medical Center

Address Line 2

Medical Arts Pavilion

Address Line 3

3400 Bainbridge Avenue

City

Bronx

State

Zip

10467

Location Title

Montefiore Medical Center

Education and Trainings

Education Type Label

Medical Education

Education Institution

University of Virginia School of Medicine

Education Type Label

Residency

Education Institution

University of Virginia Health System

Education Type Label

Residency

Education Institution

New York Presbyterian Hospital

Professional Interests

Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein.  Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
Dr. Stiles is also heavily involved with translational and basic research.  Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.   In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation. 
Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.  Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.  ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.
Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.

Research Areas

Basic/Translational:
Tumor microenvironment,
Mono-ADP-ribosylation,
ART1
Predictors of response to immunotherapy.

Clinical:
Lung cancer,
Lung cancer screening,
Neoadjuvant therapy,

Specialties

Cancer

Expert Tags

Lung Cancer

Surgical Oncology

Areas of Expertise

Lung cancer detection & treatment

Patient advocacy

Expert Summary

Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.

Research Profile

https://einsteinmed.edu/faculty/16884/Brendon-Stiles

Clinical Profile

https://montefioreeinstein.org/profiles/1013176387/brendon-m-stiles

CHAM Provider

Off

Professional Title

M.D.

Clinical Focus

Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. <quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.  In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/41add037-1c2e-4849-8877-ee4de2239…

Selected Publications

Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.  Science Translational Medicine. 2022 Mar 16;14(636):eabe8195.  <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis." Nature Reviews Cancer 19.1 (2019): 9-31.
Yao, Zhan, et al. "TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer." Proceedings of the National Academy of Sciences 107.35 (2010): 15535-15540.
Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition." Cancer research 72.6 (2012): 1384-1394.
Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial." The Lancet Oncology 22.6 (2021): 824-835.
Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells." JOURNAL FOR IMMUNOTHERAPY OF CANCER. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.
Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms." Journal of Thoracic Oncology 11.2 (2016): S44.
https://scholar.google.com/citations?user=fR4OkgkAAAAJ&hl=en&oi…;

EMR ID

82842

Biography

Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.“The recruitment of Dr. Stiles elevates the treatment of lung cancer to a historic level,” said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein. “Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.”After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.  He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.  In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.  Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.

Is Open Scheduling

Off

Subscribe to Cancer